> **Exported from granted.bio** · Live analysis: https://www.granted.bio/reports/b4bdfe2d-d0b7-4a70-9217-2e4009395011
> *This is a portable snapshot. Click through on any link to open the live analysis, follow drill-downs (projects, researchers, patents, trials), or generate your own.*

---
# Brain Organoid Electrophysiology Investment Intelligence

**Generated:** September 22, 2026
**Report Type:** Investment Intelligence
**Data Sources:** NIH RePORTER, ClinicalTrials.gov, USPTO, PubMed


---

## How to Use This Report

NIH-funded research is a leading indicator of commercial opportunity. Public funding typically precedes private activity by 3-7 years, so the projects, PIs, IP filings, and clinical programs surfaced here are early signals of which technologies will produce the next wave of companies, partnerships, and deals in this space.

The intelligence in this report comes primarily from our semantic analysis across the linked data, not from any single source. NIH RePORTER, ClinicalTrials.gov, USPTO, and PubMed are all publicly searchable - anyone can look up individual records. Our value is in:

- Identifying conceptually-related projects via AI semantic search rather than brittle keyword matching
- Cross-linking each project to its associated patents, clinical trials, and publications
- Synthesizing across the analyzed sample to surface patterns no single record reveals - competitive topology, IP concentration, field maturity, and momentum signals

The Market Context section adds external color sourced via live web search. It is supplementary to the core analysis above.


---

## What This Report Does Not Cover

*A short, upfront note on the boundaries of this analysis. We surface this so you can read everything below with the right calibration.*

- **Companies are in this data - non-NIH-funded internal R&D is not.** SBIR/STTR grantees, academic-industry partnerships, and commercial entities receiving NIH funding do appear and carry real commercial weight. What's invisible is privately-funded R&D inside companies that doesn't intersect with an NIH grant.
- **International activity is largely outside the sample.** NIH RePORTER captures US grantees and their direct collaborators. Major work in Europe, China, Japan, and elsewhere is not reflected unless tied to a US-funded project.
- **Linked outputs require an NIH grant acknowledgment.** A clinical trial, patent, or publication only appears here if it was filed with an NIH project number. Industry-led trials, non-USPTO patents, and papers without NIH funding acks are missing - even when central to the field.
- **Recent quarter activity may be incomplete.** NIH RePORTER updates with a lag of several weeks; some current-fiscal-year awards may not yet be visible.
- **Umbrella institutional grants are not credited to topic funding.** Some trials and patents in this report are hosted under broad institutional support awards (P30 cancer centers, CTSA hubs, training grants) whose parent grant covers many programs beyond this topic. Those records appear in the trials and patents sections, but the host grants' dollars are deliberately excluded from Total Committed Funding to keep the headline number topically attributable. Real topic activity at those institutions is therefore likely higher than the funding figures alone suggest.
- **Market context is web-sourced**, not exhaustive - see the Sources subsection in Market Context for what was retrieved.
- **Project categorization is automated.** A single primary category is assigned per project by AI classification, with confidence scores. Some boundary cases (especially infrastructure vs. biotools) may be misassigned.

This is depth-over-breadth analysis - high signal on what NIH funds and produces, including its commercial recipients. For pure private-market intelligence (funding rounds, M&A, internal pipelines), supplement with PitchBook, CB Insights, or industry analyst reports.
## Executive Summary

Of 122 projects totaling $129.8M across 70 organizations, the sample is split between the Biotools funding category (51 projects, 41.8%) and the Basic Research funding category (47 projects, 38.5%), with Therapeutics (13 projects, 10.7%) and Medical Device (5 projects, 4.1%) representing thin shares. Annual awards were $39.3M in FY2024 and $52.5M in FY2025, though two data points do not establish a trend. The clinical pipeline is minimal: 2 trials in progress, planned, or completed vs. 0 terminated/suspended/withdrawn (2 total), both FDA-regulated device trials with 0 randomized and 0 blinded designs, and no industry collaborators listed - consistent with a sample still concentrated in preclinical tool-building rather than clinical translation.

Within the Biotools funding category, the dominant technical bets are 3D electrode integration and MEA platforms designed to wrap or penetrate organoid geometry, plus optogenetic read/write systems for dissecting inter-region signaling. The Basic Research funding category is concentrated on cortico-striatal and neurodevelopmental disease models (epilepsy, schizophrenia, ASD), where brain organoid electrophysiology serves as the primary functional readout. IP activity in the linked sample is limited - 5 patents, 4 of which are Stanford filings covering forebrain spheroid assembly - and NIH grant administration is distributed across NINDS (4 grants), NIMH (2), and five other institutes with no single IC holding 40% or more, indicating no single programmatic owner of this space. Cross-source MeSH overlap between the trial pipeline and publications is present but narrow: epilepsy (1 trial, 2 publications) and Parkinson Disease (1 trial, 1 publication) are the only shared anchors, suggesting the research base and the clinical pipeline are addressing partially different problems.

Three watchpoints follow from the data. First, the commercialization gap between the Biotools funding category activity (51 projects, $51.8M) and the 2-trial clinical pipeline is wide; investors should watch whether FDA's April 2025 organoid-safety-testing guidance and the NIH $87M standardization commitment translate into procurement contracts or assay-validation partnerships, which would be the first revenue-adjacent signal in this sample. Second, the absence of industry collaborators across both clinical trials, and no FOA clustering (no single NIH call issued 3 or more of these grants), means there is no coordinated government-industry development push visible in this dataset - an opening for a platform company that can bridge academic tool development to pharma screening workflows. Third, the Medical Device funding category is small (5 projects, $9.1M, a low count that limits inference) and combined with 2 FDA-regulated device trials it may suggest some regulatory path clarity, though hardware-level differentiation on 3D electrode conformability and chronic signal stability remains the technical milestone separating fundable prototypes from deployable products.

---

## What Surprised Us

*Non-obvious findings detected algorithmically from the data, then interpreted. These are **flagged hypotheses**, not verified conclusions - patterns worth investigating rather than facts to act on directly. Broader NIH ratios are directional at low topic-sample counts and could reflect real gaps OR taxonomy artifacts; treat individual findings as starting points for deeper diligence.*

**1. A subset of highly-funded organizations publishes actively but shows no linked patents or trials in the NIH-linked sample**

Across 8 organizations collectively holding $53.4M in NIH funding and 145 linked publications, no patents or clinical trials appear in the NIH-acknowledged sample - a pattern that flags a potential gap between active discovery-stage output and downstream translation milestones visible through this lens. This matters because the volume of publications (145 across 35 projects) confirms research activity is real and substantial, so the absence of NIH-linked IP or trials likely reflects either a early-stage pipeline not yet reaching commercialization, or translation activity pursued through commercial channels, international filings, or industry-sponsored trials that are not captured in this sample to this dataset. Researchers scoping partners and investors evaluating pipeline maturity should treat this as a signal worth investigating further rather than evidence of a broad IP gap, since commercial and non-NIH-funded downstream work would not appear here. **Confidence: Medium** - Evidence: 8 organizations, 35 projects, $53.4M NIH funding, 145 linked publications, 0 linked trials, 0 linked patents in the NIH-acknowledged sample.

**2. A cluster of top-funded PIs hold their entire NIH-linked funding on a single project with no visible follow-on**

Six PIs among the top-funded tier collectively hold $26.9M concentrated on single-project awards, with no adjacent NIH-linked follow-on activity visible in the sample - a concentration pattern that raises questions about pipeline continuity and funding runway within this NIH-visible slice. For investors and biotech founders evaluating research relationships, single-project concentration can signal either a deliberate high-conviction bet on one program or a portfolio that has not yet diversified into follow-on validation work; without adjacent grants, the downstream trajectory of these programs is harder to assess from NIH data alone. It is worth noting that follow-on activity could exist through industry partnerships, foundation funding, or other non-NIH mechanisms that would not appear here, so this finding is best read as a prompt to investigate further rather than confirmation that no follow-on exists. **Confidence: Low** - Evidence: 6 PIs, $26.9M combined on single-project awards, 0 adjacent NIH-linked follow-on projects visible in the sample.

**3. iPSC-Derived Neural Organoid work appears largely absent from the topic sample despite a substantial broader NIH portfolio**

The topic sample contains 0 projects classified under iPSC-Derived Neural Organoid work, while roughly 248 projects match this area across the broader NIH portfolio - a gap that flags this intersection as a candidate whitespace worth investigating, though the low topic-sample count means these ratios are directional not precise and a small reclassification could shift the figure meaningfully. Before concluding this reflects a real underexplored intersection with brain organoid electrophysiology, it is important to consider alternate explanations: the topic classifier may be missing relevant work filed under adjacent terminology such as cortical spheroids, stem-cell-derived networks, or neural assembloids, and the biology of reliably driving electrophysiologically mature activity in iPSC-derived organoids is itself a known technical challenge that may limit NIH project activity in this combined space, as an aggregate pattern. This finding is best treated as a hypothesis flagged for taxonomy verification - confirming whether the 0-count reflects a true funding gap, a classification miss, or the inherent difficulty of the science would meaningfully sharpen its strategic value. **Confidence: Low** - Evidence: 0 topic-sample projects vs approximately 248 broader NIH portfolio matches on a title-only broader search; topic-slice count is highly sensitive to classification choices at this denominator.



---

## Field Maturity Assessment

*Note: This assessment is based on NIH-linked clinical trials, patents, and publications. It reflects patterns in the analyzed sample and may not represent the full global research landscape.*

**Technology Readiness:** TRL 3-4

**Overall Assessment:** Emerging - Proof of concept stage

**Historical Reference Point:** TRL 3-4 is roughly comparable to where patient-derived induced pluripotent stem cell (iPSC) disease modeling sat circa 2012-2014, when robust protocols existed in select labs but reproducibility standards, throughput, and translational relevance remained actively contested.

Brain organoid electrophysiology sits in the proof-of-concept to early lab-validation band. The 486 linked publications signal a research base that is active but still heavily anchored in basic science, the top NIH funding category is basic_research, and the clinical trial sample contains only 2 interventional trials, of which 0 carry a phase label - a subset of the 2 interventional trials in the sample - indicating no conventional therapeutic or diagnostic phase progression has been captured yet. The 5 linked patents with 0 filed in the last two years suggest intellectual property activity has not recently accelerated, and the combination of thin trial evidence and early-stage publication mix points to a field still working to standardize assays and demonstrate reproducible, translatable electrophysiological readouts before broader deployment becomes feasible.

**Confidence: Medium** - Evidence: 486 linked publications, 2 total trials with 0 phase-labeled, 5 patents with 0 recent; signals are internally consistent on early maturity but trial and patent counts are too small for high-confidence triangulation.

### Supporting Evidence

- **Publication Maturity:** With 486 linked publications, the 21% preprint ratio (roughly 100 preprints) is interpretable as a directional signal rather than a precise statistic - a meaningful minority of output has not yet completed peer review, consistent with an active but still-consolidating field where methods and standards are being refined in real time.

**Confidence: Medium** - Evidence: 486 total linked publications, ~100 preprints estimated at 21% ratio; ratio is directionally meaningful at this publication count but not a high-precision measure.
- **Clinical Progression:** With only 2 total linked trials, phase distribution must be treated as descriptive only and cannot support statistical inference; both trials are interventional and classified as N/A phase, 2 interventional trials with 0 carrying a phase label, and 0 are randomized or double-blinded, with 1 of 2 having a Data Monitoring Committee present - a pattern consistent with early feasibility or device-safety framing rather than efficacy testing.

**Confidence: Low** - Evidence: 2 total trials, 2 interventional, 0 phase-labeled, 0 randomized, 0 double-blinded, 1 DMC; sample is too small for distributional claims.
- **IP Activity:** With only 5 linked patents, the 0% recency ratio (0 filed in the last two years) is not reliably interpretable as a trend signal; the small absolute count means a single new filing would materially shift the ratio, so the observed recency gap reflects sample sparsity as much as any field-level IP dynamic.

**Confidence: Low** - Evidence: 5 total linked patents, 0 in the last two years; sample too small to treat recency ratio as a meaningful trend indicator.

### Strategic Implications

For an investor, brain organoid electrophysiology at TRL 3-4 is a pre-commercial, high-optionality space most appropriate for seed or Series A positioning in platform-tool companies rather than near-term therapeutic bets - the linked sample of 122 NIH projects totaling $129.8M (with FY2024 at $39.3M and FY2025 at $52.5M in the linked sample, though two data points do not establish a trend) indicates sustained public funding that can de-risk early R&D, but the absence of any phase-labeled trials and the thin patent pipeline (5 linked patents, 0 recent) suggest commercial milestones are still multiple development steps away. Diligence should focus on companies that can demonstrate reproducible, standardized electrophysiological readouts across organoid batches - inter-batch variability and throughput are the technical milestones most likely to gate downstream value - and on whether the regulatory pathway for FDA-regulated device applications (both linked trials are FDA-regulated device trials) can be clarified, since device classification may offer a faster route to market than a drug-based strategy. The basic_research category is the largest single funding category in the linked sample, accounting for the majority of the 122 projects, which suggests the field has not yet produced a dominant translational playbook; this creates both risk and an opening for investors who can identify teams bridging organoid biology to scalable assay formats before the field converges on a standard.

**Confidence: Medium** - Evidence: 122 NIH projects, $129.8M total linked funding, 2 FDA-regulated device trials of 2 total linked trials, 5 linked patents with 0 recent, 0 phase-labeled trials across 2 interventional; consistent early-stage signals but small trial and patent counts limit confidence.
## Competitive Topology

*Note: Key players listed below are derived from NIH-funded project data and represent academic/research institutions. Commercial entities may not appear. The 5 clusters below are the methodological groupings the synthesis identified as most distinct in the analyzed abstracts - clusters are cross-cutting (a single project can belong to more than one), and a different cut of the data could resolve at 3 or 6 clusters rather than 5.*

Among the funded projects in this sample, the competitive topology for brain organoid electrophysiology is organized around five distinct technical approaches that exist on a maturity gradient: high-density silicon probe recording (Maturing) and assembloid multi-region circuit platforms (Emerging) represent the highest-volume clusters by project count and funding, while MEA-based organoid platforms and optogenetic-optical electrophysiology occupy a comparable Emerging tier with active SBIR commercial translation occurring in parallel to academic development.

**Confidence: High** - Evidence: 40+ projects mapped across 5 clusters, with several top-funded institutions each spanning multiple clusters simultaneously, indicating that competition is methodological rather than institutional.

The nascent 3D nanoelectronic intracellular recording cluster is technically distinct from all others and carries the highest development risk but also the highest potential differentiation relative to incumbent MEA-based approaches; the patent record (Yale planar patch clamp, Stanford spheroid assembly) skews toward organoid biology rather than the recording hardware layer, suggesting IP opportunity in the interface and integration space.

**Confidence: Medium** - Evidence: 2 linked patents in sample both on organoid biology side; hardware-layer patents not captured in NIH-linked patent data provided, limiting full IP topology assessment.

### Methodological Clusters

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 1 | **Microelectrode Array (MEA) and Multi-Electrode Array Platforms for Organoid Electrophysiology** | NEURONEXUS TECHNOLOGIES (commercial, R43MH139259), CFD RESEARCH CORPORATION (commercial, R41TR006349), JOHNS HOPKINS UNIVERSITY (R21NS145047), UNIVERSITY OF MASSACHUSETTS AMHERST (R21AG087754), ... | Emerging | MEA-based organoid recording platforms are transitioning from academic prototypes toward commercial instruments, with at least 3 SBIR/STTR-phase companies (NeurоNexus, CFD Research, LeafLabs) actively developing products, though long-term stable recording in 3D organoid geometries remains an engineering challenge that limits near-term product readiness. |

**Confidence: High** - Evidence: 9+ projects spanning academic labs and commercial SBIR grantees, with the HOPES platform (CFD Research) and NeurоNexus system both in R41/R43 Phase I commercial development.

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 2 | **Optogenetic Stimulation and Optical Electrophysiology in Organoids and Neural Circuits** | NEUROLUX, INC. (commercial, 1R43MH143569-01), UNIVERSITY OF MASSACHUSETTS AMHERST (5R21AG087754-03), STANFORD UNIVERSITY (R01NS124590), UNIVERSITY OF CALIFORNIA BERKELEY (5R01NS098088-10, 1RF1NS131075-01, R34NS144925), ... | Emerging | All-optical electrophysiology (combining optical stimulation and voltage imaging) is approaching early commercial deployment for drug screening applications - Quiver Bioscience holds an R44 award targeting functional drug fingerprinting, and NeurоLux targets organoid-specific optogenetic actuation - but organoid-specific optical tools with sufficient spatial resolution for 3D tissue volumes remain at the prototype stage. |

**Confidence: High** - Evidence: 9+ projects across multiple institutions and 2 commercial SBIR grantees (Quiver Bioscience R44, NeurоLux R43), with cross-cluster corroboration from Stanford patent filings on forebrain spheroid assembly.

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 3 | **High-Density Silicon Probe and Flexible Electrode Array Recording (Neuropixels-class and Ultraflexible Probes)** | ALLEN INSTITUTE (5U01NS133760-03, R01NS120300, 1RF1MH128840-01), JOHNS HOPKINS UNIVERSITY (5U01NS115587-04, R01NS142455), UNIVERSITY OF SOUTHERN CALIFORNIA (5U01NS126046-04), RICE UNIVERSITY (5U01NS131086-03), ... | Maturing | High-density silicon probe technology is the most commercially mature cluster in this sample - Neuropixels-derived probes are already in wide academic use, and SpikeGadgets holds two commercialization awards (R43 and R44) for integrated electrode-electronics systems targeting freely moving animal recording - with near-term revenue potential from primate and chronic recording markets. |

**Confidence: High** - Evidence: 8+ projects including three U01 large-scale awards totaling substantial NIH investment, two SpikeGadgets commercial awards, and active primate validation work at Allen Institute ($17.8M top funder in sample).

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 4 | **3D Intracellular Recording via Nanoscale Transistors, Nanoelectronics, and Novel Substrate Interfaces** | UNIVERSITY OF CALIFORNIA, SAN DIEGO (R35GM138250), HARVARD UNIVERSITY (5DP1DK130673-05, R01LM014465), MASSACHUSETTS INSTITUTE OF TECHNOLOGY (5R01HL172065-02), UNIVERSITY OF CHICAGO (4DP1GM149751-04), ... | Nascent | 3D field-effect transistor arrays and nanoelectronic interfaces for intracellular recording represent the earliest-stage cluster in this sample - current work is focused on demonstrating proof-of-concept recording fidelity in cellular networks rather than system integration - and commercial timelines are likely 5-10 years out pending materials and fabrication scale-up. |

**Confidence: Medium** - Evidence: 6 projects across 5 institutions with no cross-linked clinical trials in sample; one commercial SBIR awardee (Applied Nanostructures R44) but no Phase II conversion data visible in this dataset.

---

| # | Approach | Key Players | Maturity | Commercial Readiness |
|---|----------|-------------|----------|---------------------|
| 5 | **Assembloid and Multi-Region Organoid Circuit Platforms with Integrated Functional Readouts** | STANFORD UNIVERSITY (R01MH107800, 2R37MH107800-11, 5R01MH137333-02, R01NS136675-02), UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH (R01NS123849), CINCINNATI CHILDRENS HOSP MED CTR (5R21MH132038-02), COLUMBIA UNIVERSITY HEALTH SCIENCES (4DP2MH132944-02), ... | Emerging | Assembloid platforms integrating multiple brain regions with electrophysiological or imaging readouts are gaining traction as disease-modeling and drug-screening tools, with the DROID platform at Johns Hopkins (UM1TR006046) and the organoid-brain-chip at LeafLabs (R44AA033838) representing the leading translational examples, though reproducibility and standardization challenges are the primary barriers to commercial adoption. |

**Confidence: High** - Evidence: 10+ projects across at least 8 institutions, two Stanford forebrain spheroid patents directly linked to this approach, and disease-modeling applications spanning schizophrenia, epilepsy, autism, and ALS across the sample.

### Strategic Implications

For investors, the high-density silicon probe cluster is closest to commercial deployment and generates near-term revenue from academic and pharma research tool sales, but first-mover positions are largely occupied and exit optionality depends on primate-scale and chronic-recording differentiation rather than platform novelty. The MEA-organoid and assembloid platform clusters represent the highest near-term investment opportunity in terms of balancing technical risk against addressable market: multiple SBIR Phase I-to-II transitions are actively underway, drug screening validation milestones (reproducible network oscillations, pharmacological benchmarking) are tractable within 2-4 year investment horizons, and the lack of a dominant commercial standard creates acquisition optionality. The 3D nanoelectronic intracellular recording approach carries the longest time-to-revenue but is the most technically differentiated from existing commercial tools; a seed or Series A position here is best framed as a platform bet contingent on demonstrated multi-cell simultaneous intracellular recording in a 3D organoid context as the de-risking milestone. Optogenetic-optical electrophysiology for drug fingerprinting (with at least one R44 commercial award in sample) is the approach most likely to reach a pharma partnership or licensing deal in the near term, making it relevant for investors who prioritize milestone-linked deal structures over product-company exits.

**Confidence: Medium** - Evidence: 5 clusters identified from 122 projects; commercial translation signals from 6 SBIR/STTR grantees in sample; no Phase III clinical trials linked to organoid electrophysiology in the clinical development section, limiting confidence in near-term revenue timing estimates.



---

## Industry Engagement

Of 2 clinical trials in this landscape:

- **0 (0%)** industry-lead (lead sponsor class INDUSTRY on ClinicalTrials.gov)
- **0 (0%)** academic- or NIH-led with an industry collaborator
- **2 (100%)** academic / NIH only (no industry sponsor or collaborator)

**Signal:** No industry engagement across the surfaced trial set. This landscape is currently NIH- and academic-driven.

*Method: sponsor and collaborator classes are source-truth from ClinicalTrials.gov (protocolSection.sponsorCollaboratorsModule.leadSponsor.class and collaborators[].class). Coverage varies by trial vintage - some older trials predate CT.gov's sponsor classification and are counted as "no data" rather than "not engaged".*

---

## White Space Analysis

*This section maps what NIH-funded research covers vs. what's underrepresented within the topic scope. Private R&D, international research, and non-NIH federal funding (DoD, DARPA, industry) are not captured here. Broader-NIH counts are filtered to brain organoid electrophysiology scope so comparisons are topically apples-to-apples. **Sample counts** match against title AND abstract for the analyzed project set; **broader-NIH counts** match against title ONLY (abstracts aren't full-text-indexed at query time), so broader counts are directional lower bounds.*

> **Base rate for "Broader NIH" columns:** every broader-NIH cell below is drawn from **2,299 NIH projects** matching the brain organoid electrophysiology scope filter - not the full ~154K RePORTER universe. Read broader-NIH counts as shares of that 2,299-project scope, not of all NIH funding.

> **How to read this section.** Each of the 5 dimensions below is a different axis (e.g., Production Platform, Therapeutic Target). For each project we check whether its title or abstract mentions any keyword in any of that dimension's categories. If yes, the project is *matched* on that axis. If no, it's *unclassified* on that axis - usually because the project doesn't foreground that particular axis (a "cell-free antibody discovery for HIV" project foregrounds Engineering and Therapeutic Target but rarely names a specific Antibody Format, so it lands unclassified on Format). **A project can be matched on some axes and unclassified on others.** High unclassified rates on an axis typically mean the sample doesn't foreground that axis - not that the projects are broken or the taxonomy is wrong.

### Overview

Across 122 NIH-funded projects totaling $129.8M, coverage of brain organoid electrophysiology is densest around Multi-Electrode Array recording (21 projects, 17.2%), whole/unguided cerebral organoid architectures (27 projects, 22.1%), and rodent/non-human primate in vivo models (36 projects, 29.5%), while disease-specific and circuit-level dimensions remain comparatively thin. The Disease/Neurological Condition Modeled dimension is heavily dominated by unspecified healthy-development baselines (63 projects, 51.6%), leaving most named disorders with only 1-4 projects each. Platform engineering coverage clusters around multimodal sensor approaches (19 projects, 15.6%) but shows near-zero activity in machine learning pipelines and connectome integration. These figures reflect publicly searchable NIH RePORTER federal funding - the largest single source of US non-dilutive biomedical grants - but exclude private industry R&D, international programs, and non-NIH federal funding, so actual global activity in some categories may be higher than these counts suggest.

**Confidence: High** - Evidence: 122 projects, 5 dimensions, strong sample match (86.9% on-topic); broader NIH counts are conservative title-only floor estimates.

### Coverage by Electrophysiology Recording Modality

*The specific electrophysiological measurement technique used to interrogate organoid or neural circuit activity*

<!-- chart:white-space-dimension:0 -->

| Category | Projects | % of Sample | Funding | Broader NIH (brain organoid electrophysiology) |
|----------|---------:|------------:|--------:|------------:|
| Patch Clamp / Whole-Cell Recording | 11 | 9.0% | $12.1M | 11 |
| Multi-Electrode Array (MEA) | 21 | 17.2% | $21.0M | 4 |
| Silicon Probe / High-Density Extracellular Recording | 10 | 8.2% | $17.4M | 2 |
| Local Field Potential & Population Activity | 3 | 2.5% | $2.3M | 1 |
| Optical Voltage Imaging / Voltage Indicators | 11 | 9.0% | $9.5M | 9 |
| Calcium Imaging as Surrogate Electrophysiology | 0 | 0.0% | $0.0M | 0 |
| Electrical Stimulation & Evoked Response Recording | 5 | 4.1% | $4.0M | 17 |
| Long-Term / Longitudinal Electrophysiological Profiling | 6 | 4.9% | $5.2M | 0 |
| Intracellular / Nanoscale Electrode Recording | 10 | 8.2% | $7.4M | 2 |
| Optogenetics-Coupled Electrophysiology | 3 | 2.5% | $2.1M | 8 |

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 80 classified projects.*

*Keywords per category (what was counted):*

- **Patch Clamp / Whole-Cell Recording**: `patch clamp`, `whole cell recording`, `whole-cell patch`, `patch-clamp`, `voltage clamp`, `current clamp`, `intracellular recording`, `gigaseal`, `automated patch clamp`, `single-cell electrophysiology`
- **Multi-Electrode Array (MEA)**: `multi-electrode array`, `mea`, `microelectrode array`, `multielectrode array`, `electrode array`, `mefa`, `mea recording`, `high-density mea`, `planar mea`
- **Silicon Probe / High-Density Extracellular Recording**: `silicon probe`, `neuropixels`, `extracellular recording`, `high-density probe`, `shank electrode`, `laminar probe`, `polytrode`, `large-scale recording`, `single-unit recording`, `spike sorting`
- **Local Field Potential & Population Activity**: `local field potential`, `lfp`, `field potential`, `field oscillation`, `population activity`, `network oscillation`, `gamma oscillation`, `beta oscillation`, `theta oscillation`, `brain wave`
- **Optical Voltage Imaging / Voltage Indicators**: `voltage imaging`, `optical voltage`, `voltage indicator`, `gevi`, `genetically encoded voltage indicator`, `voltage dye`, `optical electrophysiology`, `action potential imaging`, `voltage-sensitive dye`
- **Calcium Imaging as Surrogate Electrophysiology**: `calcium imaging`, `gcamp`, `calcium indicator`, `fluorescence calcium`, `calcium transient`, `neural calcium`, `two-photon calcium`, `calcium dynamics`, `genetically encoded calcium indicator`, `geci`
- **Electrical Stimulation & Evoked Response Recording**: `electrical stimulation`, `evoked potential`, `evoked response`, `stimulus-evoked`, `electric stimulation`, `neuromodulation`, `stimulation-induced`, `pulse stimulation`, `charge injection`, `neural stimulation`
- **Long-Term / Longitudinal Electrophysiological Profiling**: `long-term recording`, `longitudinal recording`, `chronic recording`, `temporally scalable`, `long-term electrophysiology`, `continuous recording`, `sustained electrophysiological`, `long-term profiling`, `real-time monitoring`
- **Intracellular / Nanoscale Electrode Recording**: `intracellular recording`, `intracellular electrode`, `nanopillar`, `nanoelectrode`, `nanowire electrode`, `intracellular access`, `tight-seal intracellular`, `sub-cellular recording`
- **Optogenetics-Coupled Electrophysiology**: `optogenetic`, `optogenetics`, `channelrhodopsin`, `opsin`, `light-activated`, `opto-electrophysiology`, `dual-color optogenetic`, `all-optical electrophysiology`, `optical stimulation recording`, `optoelectrophysiology`

In the Electrophysiology Recording Modality dimension, 80 of 122 projects were classifiable, with Multi-Electrode Array (MEA) as the dominant category at 21 projects (17.2% of sample) and $21.0M - well ahead of Patch Clamp (11 projects, 9.0%) and Optical Voltage Imaging (11 projects, 9.0%). Calcium Imaging as Surrogate Electrophysiology is entirely absent (0 projects, 0 broader NIH matches), while Optogenetics-Coupled Electrophysiology and Local Field Potential approaches each appear in only 3 projects (2.5%) within this dimension, though the broader NIH counts for those categories (8 and 1 respectively) are too sparse to draw coverage conclusions. Long-Term/Longitudinal Electrophysiological Profiling has 6 projects (4.9%) in this dimension with 0 broader NIH matches, suggesting this may be a topic-specific methodological niche rather than a field-wide gap.

**Confidence: High** - Evidence: 80 matched projects, 10 categories; MEA top concentration at 17.2% of sample; 42 unclassified projects noted.

### Coverage by Organoid / Model System Architecture

*The structural and biological composition of the organoid or in vitro neural model used in the study*

<!-- chart:white-space-dimension:1 -->

| Category | Projects | % of Sample | Funding | Broader NIH (brain organoid electrophysiology) |
|----------|---------:|------------:|--------:|------------:|
| Brain Organoid (Whole / Unguided Cerebral) | 27 | 22.1% | $29.4M | 85 [†] |
| Region-Specific Neural Organoid | 2 | 1.6% | $1.4M | 19 |
| Assembloid / Fused Multi-Region Organoid | 5 | 4.1% | $3.7M | 5 |
| iPSC-Derived Neural Organoid | 0 | 0.0% | $0.0M | 248 [†] |
| Neurovascular / Gliovascular Organoid | 1 | 0.8% | $0.4M | 1 |
| Organ-on-Chip / Microfluidic Brain Circuit | 3 | 2.5% | $1.5M | 3 |
| 2D Neural Culture / Dissociated Neuron Network | 1 | 0.8% | $0.8M | 0 |
| Non-Brain / Comparative Organoid Model | 19 | 15.6% | $14.4M | 19 |
| Rodent / Non-Human Primate In Vivo Model | 36 | 29.5% | $44.7M | 17 |
| Activity-Augmented / Maturation-Enhanced Organoid | 1 | 0.8% | $1.0M | 5 |

> [†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 95 classified projects.*

*Keywords per category (what was counted):*

- **Brain Organoid (Whole / Unguided Cerebral)**: `brain organoid`, `cerebral organoid`, `whole brain organoid`, `unguided organoid`, `self-organized organoid`, `lancaster organoid`, `cerebral organoid electrophysiology`, `human brain organoid`
- **Region-Specific Neural Organoid**: `cortical organoid`, `hippocampal organoid`, `striatal organoid`, `thalamic organoid`, `cerebellar organoid`, `choroid plexus organoid`, `region-specific organoid`, `patterned organoid`, `guided organoid`, `forebrain organoid`
- **Assembloid / Fused Multi-Region Organoid**: `assembloid`, `fused organoid`, `cortico-striatal organoid`, `organoid fusion`, `multi-region organoid`, `brain assembloid`, `cortico-thalamic assembloid`, `spinal assembloid`, `organoid circuit`, `cortico-striatal network`
- **iPSC-Derived Neural Organoid**: `ipsc`, `induced pluripotent stem cell`, `hipsc`, `ipsc-derived`, `ipsc organoid`, `patient-derived ipsc`, `reprogrammed stem cell`, `pluripotent stem cell organoid`, `ipsc neural`, `stem cell-derived organoid`
- **Neurovascular / Gliovascular Organoid**: `neurovascular organoid`, `vascularized organoid`, `blood-brain barrier organoid`, `endothelial organoid`, `gliovascular`, `neurovascular unit`, `vessel organoid`, `vascular neural organoid`, `bbb organoid`
- **Organ-on-Chip / Microfluidic Brain Circuit**: `organ-on-chip`, `brain-on-chip`, `organoid-on-chip`, `microfluidic organoid`, `brain chip`, `3d brain circuit`, `on-chip circuit`, `brain circuit chip`, `microphysiological system`, `mps`
- **2D Neural Culture / Dissociated Neuron Network**: `dissociated neuron`, `2d neural culture`, `neuronal monolayer`, `primary neuron culture`, `cortical neuron culture`, `2d culture electrophysiology`, `planar neural network`, `neuronal network in vitro`, `neural sheet`
- **Non-Brain / Comparative Organoid Model**: `cardiomyocyte organoid`, `cardiac organoid`, `retinal organoid`, `tooth organoid`, `gut organoid`, `kidney organoid`, `non-brain organoid`, `comparative organoid`, `sensory organoid`, `tooth root organoid`
- **Rodent / Non-Human Primate In Vivo Model**: `rodent model`, `mouse model`, `rat model`, `non-human primate`, `primate model`, `in vivo rodent`, `monkey electrophysiology`, `in vivo neural`, `in vivo recording`, `animal model electrophysiology`
- **Activity-Augmented / Maturation-Enhanced Organoid**: `activity augmented`, `maturation enhanced`, `organoid maturation`, `functional maturation`, `activity-dependent maturation`, `postnatal organoid`, `matured organoid`, `organoid development stage`, `functionally mature organoid`

In the Organoid/Model System Architecture dimension, 95 of 122 projects were classifiable, but the distribution is skewed toward in vivo rodent/non-human primate models (36 projects, 29.5%) and whole/unguided cerebral brain organoids (27 projects, 22.1%), together suggesting the sample bridges classical animal neuroscience with organoid approaches rather than focusing exclusively on organoid-native systems. iPSC-Derived Neural Organoid is completely absent from the analyzed sample (0 projects, 0.0%) despite 248 broader NIH matches - a disparity that warrants attention given how central iPSC derivation is to organoid biology broadly. Region-Specific Neural Organoids appear in only 2 projects (1.6%) in this dimension, and Activity-Augmented/Maturation-Enhanced Organoids in just 1 project (0.8%), both with modest broader NIH footprints that are below the threshold for drawing strong gap conclusions.

**Confidence: High** - Evidence: 95 matched projects, 10 categories; iPSC absence is the standout signal; broader NIH count of 248 for iPSC is anomalous relative to peer categories in this dimension (median peer broader NIH ~10) and likely reflects the broad general prevalence of iPSC terminology across all of stem-cell biology - treat as directional.

### Coverage by Disease / Neurological Condition Modeled

*The specific neurological disorder, developmental condition, or disease context being studied using organoid electrophysiology*

<!-- chart:white-space-dimension:2 -->

| Category | Projects | % of Sample | Funding | Broader NIH (brain organoid electrophysiology) |
|----------|---------:|------------:|--------:|------------:|
| Autism Spectrum Disorder / Syndromic ASD | 1 | 0.8% | $0.6M | 63 |
| Epilepsy / Seizure Disorder | 2 | 1.6% | $0.6M | 46 |
| Schizophrenia / Psychiatric Disorder | 4 | 3.3% | $5.8M | 40 |
| Alzheimer's Disease / Age-Related Neurodegeneration | 1 | 0.8% | $6.2M | 92 |
| Parkinson's Disease / Synucleinopathy | 0 | 0.0% | $0.0M | 38 |
| Neurodevelopmental Disorder (Broad / Intellectual Disability) | 9 | 7.4% | $6.4M | 55 |
| Viral / Infectious Neurological Disease (Zika, COVID) | 0 | 0.0% | $0.0M | 12 |
| Traumatic Brain Injury / Stroke / Ischemia | 1 | 0.8% | $0.6M | 39 |
| Movement Disorder / Cortico-Striatal Dysfunction | 0 | 0.0% | $0.0M | 26 |
| Drug Discovery / Pharmacological Disease Model | 7 | 5.7% | $5.6M | 19 |
| Unspecified / Healthy Neural Development Baseline | 63 | 51.6% | $73.6M | 2 |

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 88 classified projects.*

*Keywords per category (what was counted):*

- **Autism Spectrum Disorder / Syndromic ASD**: `autism`, `asd`, `autism spectrum`, `rett syndrome`, `fragile x`, `timothy syndrome`, `angelman syndrome`, `pten`, `syndromic autism`, `social brain disorder`
- **Epilepsy / Seizure Disorder**: `epilepsy`, `seizure`, `epileptic`, `channelopathy`, `scn8a`, `scn1a`, `dravet syndrome`, `hyperexcitability`, `ictogenesis`, `seizure-like activity`, `epileptiform`
- **Schizophrenia / Psychiatric Disorder**: `schizophrenia`, `psychiatric disorder`, `psychosis`, `bipolar disorder`, `disc1`, `psychiatric disease`, `22q11`, `mental illness`, `psychotic disorder`, `neurodevelopmental psychiatric`
- **Alzheimer's Disease / Age-Related Neurodegeneration**: `alzheimer`, `alzheimer's disease`, `amyloid`, `tau pathology`, `neurodegeneration`, `dementia`, `age-related neurodegeneration`, `ad organoid`, `amyloid beta`, `neurofibrillary`
- **Parkinson's Disease / Synucleinopathy**: `parkinson`, `parkinson's disease`, `alpha-synuclein`, `synucleinopathy`, `dopaminergic`, `lrrk2`, `pink1`, `parkin`, `substantia nigra`, `dopamine neuron loss`
- **Neurodevelopmental Disorder (Broad / Intellectual Disability)**: `neurodevelopmental disorder`, `intellectual disability`, `developmental delay`, `cortical development`, `brain development`, `human neurodevelopment`, `neurodevelopmental disease`, `cognitive disability`, `ndd`, `human brain development`
- **Viral / Infectious Neurological Disease (Zika, COVID)**: `zika`, `zikv`, `covid`, `sars-cov-2`, `neurotropic virus`, `viral encephalitis`, `infectious neurological`, `viral brain injury`, `neuroinflammation virus`, `congenital zika`
- **Traumatic Brain Injury / Stroke / Ischemia**: `traumatic brain injury`, `tbi`, `stroke`, `ischemia`, `ischemic brain`, `cerebral ischemia`, `brain trauma`, `concussion`, `hypoxia neural`, `brain injury model`
- **Movement Disorder / Cortico-Striatal Dysfunction**: `huntington`, `huntington's disease`, `cortico-striatal`, `basal ganglia disorder`, `movement disorder`, `striatal dysfunction`, `motor circuit`, `motor disorder`, `corticostriatal circuit`, `motor neuron disease`
- **Drug Discovery / Pharmacological Disease Model**: `drug discovery`, `drug screening`, `pharmacological model`, `neurotoxicity`, `drug target`, `therapeutic screening`, `neuropharmacology`, `disease modeling drug`, `preclinical drug`, `high-throughput drug`
- **Unspecified / Healthy Neural Development Baseline**: `healthy control`, `normal development`, `baseline neural`, `wild-type organoid`, `control organoid`, `normative electrophysiology`, `healthy brain development`, `developmental baseline`, `non-disease organoid`

In the Disease/Neurological Condition Modeled dimension, 88 of 122 projects were classifiable, and the single most striking feature is that 63 projects (51.6%) fall into the Unspecified/Healthy Neural Development Baseline category, leaving disease-specific work fragmented across small clusters. Alzheimer's Disease appears in only 1 project (0.8%) in this dimension despite 92 broader NIH matches, and Autism Spectrum Disorder similarly appears in just 1 project (0.8%) versus 63 broader NIH matches, both representing substantial divergence between the analyzed topic sample and the broader NIH portfolio. Parkinson's Disease, Viral/Infectious Neurological Disease, and Movement Disorder each have 0 projects in this dimension; their broader NIH counts range from 12 to 38, but only those at or above 30 (Parkinson's at 38, Movement Disorder at 26) approach the threshold for drawing directional conclusions - and Movement Disorder at 26 falls just below it.

**Confidence: High** - Evidence: 88 matched projects, 11 categories; healthy-baseline concentration at 51.6%; 34 unclassified projects noted.

### Coverage by Platform Technology & Engineering Approach

*The hardware, fabrication, or engineering innovation enabling electrophysiological measurement in organoid systems*

<!-- chart:white-space-dimension:3 -->

| Category | Projects | % of Sample | Funding | Broader NIH (brain organoid electrophysiology) |
|----------|---------:|------------:|--------:|------------:|
| Scalable / High-Throughput Electrophysiology Platform | 10 | 8.2% | $8.1M | 20 [†] |
| Flexible / Compliant Electrode & Bioelectronic Interface | 6 | 4.9% | $6.3M | 1 |
| Microfluidic / Fluidic Integration with Electrode | 5 | 4.1% | $3.4M | 1 |
| Silicon Probe / CMOS-Integrated Electrode Fabrication | 5 | 4.1% | $10.5M | 2 |
| 3D Scaffold / Embedded Electrode Architecture | 10 | 8.2% | $8.3M | 0 |
| Long-Term Culture & Recording System Integration | 7 | 5.7% | $7.4M | 2 |
| Multimodal Sensor / Co-Registered Optical-Electrical Platform | 19 | 15.6% | $16.4M | 0 |
| Machine Learning / Computational Analysis Pipeline | 2 | 1.6% | $1.5M | 11 [†] |
| Connectome / Transcriptome Integration with Electrophysiology | 2 | 1.6% | $4.6M | 0 |
| Optogenetic Tool / Probe Development | 3 | 2.5% | $2.1M | 3 |

> [†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 69 classified projects.*

*Keywords per category (what was counted):*

- **Scalable / High-Throughput Electrophysiology Platform**: `high-throughput`, `scalable electrophysiology`, `automated electrophysiology`, `hopes`, `throughput platform`, `large-scale platform`, `parallel recording`, `high-throughput organoid`, `scalable recording`, `electrophysiology platform`
- **Flexible / Compliant Electrode & Bioelectronic Interface**: `flexible electrode`, `compliant electrode`, `soft bioelectronics`, `flexible mea`, `stretchable electrode`, `soft electrode`, `conformable electrode`, `bioelectronic interface`, `reversible actuator`, `cradle`
- **Microfluidic / Fluidic Integration with Electrode**: `microfluidic electrode`, `fluidic array`, `mefa`, `micro electrode fluidic`, `integrated fluidic`, `microfluidic mea`, `perfusion electrode`, `lab-on-chip electrode`, `fluid delivery electrode`, `organ-chip electrode`
- **Silicon Probe / CMOS-Integrated Electrode Fabrication**: `silicon probe fabrication`, `cmos electrode`, `neuropixels nxt`, `integrated silicon probe`, `asic electrode`, `complementary metal oxide`, `microfabricated probe`, `high-density silicon`, `vlsi neural probe`, `nanofabricated electrode`
- **3D Scaffold / Embedded Electrode Architecture**: `3d scaffold electrode`, `embedded electrode`, `3d mea`, `three-dimensional electrode`, `scaffold recording`, `3d bioelectronics`, `3d neural probe`, `embedded mea`, `3d electrode array`, `volumetric electrode`
- **Long-Term Culture & Recording System Integration**: `long-term culture system`, `culture recording system`, `bioreactor electrophysiology`, `sustained culture recording`, `incubator mea`, `long-term electrophysiological profiling`, `culture maintenance recording`, `integrated culture system`, `closed-loop culture`, `perfusion culture recording`
- **Multimodal Sensor / Co-Registered Optical-Electrical Platform**: `multimodal sensor`, `multimodal mea`, `optical electrical co-registration`, `combined imaging electrophysiology`, `multi-modal recording`, `photonic integrated`, `optoelectronic probe`, `optical fiber electrode`, `multi-modal platform`, `hybrid sensor`
- **Machine Learning / Computational Analysis Pipeline**: `machine learning`, `deep learning`, `neural network analysis`, `computational electrophysiology`, `spike sorting algorithm`, `automated analysis`, `ai electrophysiology`, `signal processing pipeline`, `data-driven analysis`, `convolutional neural network`
- **Connectome / Transcriptome Integration with Electrophysiology**: `connectome`, `connectomics`, `transcriptome integration`, `patchlink`, `multiomics electrophysiology`, `single-cell transcriptomics electrophysiology`, `projectome`, `spatial transcriptomics organoid`, `connectome electrophysiology`, `patch-seq`
- **Optogenetic Tool / Probe Development**: `optogenetic probe`, `dual-color optogenetic`, `opsin development`, `channelrhodopsin variant`, `optogenetic tool`, `chemogenetic`, `dreadd`, `opsin engineering`, `light-gated channel`, `optogenetic actuator`

In the Platform Technology and Engineering Approach dimension, 69 of 122 projects were classifiable, with Multimodal Sensor/Co-Registered Optical-Electrical Platform as the leading category at 19 projects (15.6% of sample) and $16.4M - notably with 0 broader NIH matches, suggesting this framing is specific to the organoid electrophysiology topic rather than a general NIH theme. 3D Scaffold/Embedded Electrode Architecture and Scalable/High-Throughput Electrophysiology Platform each appear in 10 projects (8.2%) in this dimension, while Machine Learning/Computational Analysis Pipeline and Connectome/Transcriptome Integration each appear in only 2 projects (1.6%), despite the broader NIH showing 11 matches for ML pipelines. Flexible/Compliant Electrode and Microfluidic/Fluidic Integration approaches each appear in 5-6 projects (4.1%-4.9%) in this dimension with near-zero broader NIH counts, suggesting these engineering niches are tracked primarily within organoid-specific research communities.

**Confidence: Medium** - Evidence: 69 matched projects, 10 categories; 53 unclassified projects limit interpretability; multimodal sensor top concentration at 15.6%.

### Coverage by Neural Circuit / Cell-Type Focus

*The specific neural circuit architecture, brain region interaction, or cell-type identity being electrophysiologically characterized*

<!-- chart:white-space-dimension:4 -->

| Category | Projects | % of Sample | Funding | Broader NIH (brain organoid electrophysiology) |
|----------|---------:|------------:|--------:|------------:|
| Cortical Circuit / Neocortical Layer Dynamics | 9 | 7.4% | $13.5M | 167 [†] |
| Cortico-Striatal / Basal Ganglia Circuit | 2 | 1.6% | $1.3M | 15 |
| Hippocampal / Memory Circuit | 1 | 0.8% | $0.5M | 11 |
| Excitatory / Glutamatergic Neuron | 1 | 0.8% | $0.1M | 11 |
| Inhibitory / GABAergic Interneuron | 1 | 0.8% | $1.3M | 55 |
| Dopaminergic / Monoaminergic Circuit | 0 | 0.0% | $0.0M | 44 |
| Glial Cell / Non-Neuronal Electrophysiology | 4 | 3.3% | $5.4M | 114 [†] |
| Synaptic Transmission & Plasticity | 1 | 0.8% | $1.3M | 12 |
| Inter-Organoid / Long-Range Network Connectivity | 5 | 4.1% | $3.6M | 5 |
| Cell-Type-Specific Targeting & Genetic Identity | 8 | 6.6% | $12.2M | 8 |
| Sensory / Peripheral-Innervation Circuit | 5 | 4.1% | $3.9M | 42 |

> [†] Rows marked with a dagger are broader-NIH outliers - either their broader count is much higher than the dimension median (>=5x) or the category name contains a generic biomedical term ("machine learning", "biomarker", "methylation") that over-matches within the topic scope. These counts likely reflect generic keyword prevalence within the scope-filtered universe rather than topic-specific activity. Treat as directional only; do not anchor coverage inferences on daggered cells.

*Rows are non-exclusive: a project can appear in more than one category, so the sum of the Projects column can exceed 41 classified projects.*

*Keywords per category (what was counted):*

- **Cortical Circuit / Neocortical Layer Dynamics**: `cortical circuit`, `neocortical`, `cortical layer`, `cortical column`, `cortical neuron`, `cortical network`, `cortical electrophysiology`, `neocortex`, `cortical oscillation`, `corticogenesis`
- **Cortico-Striatal / Basal Ganglia Circuit**: `cortico-striatal`, `corticostriatal`, `basal ganglia`, `striatal circuit`, `striatum`, `cortico-striatal connectivity`, `basal ganglia circuit`, `striatal neuron`, `cortico-basal`, `corticobasal`
- **Hippocampal / Memory Circuit**: `hippocampal circuit`, `hippocampus`, `hippocampal network`, `memory circuit`, `ca1`, `ca3`, `dentate gyrus`, `hippocampal oscillation`, `place cell`, `hippocampal organoid`
- **Excitatory / Glutamatergic Neuron**: `excitatory neuron`, `glutamatergic`, `pyramidal neuron`, `ampa receptor`, `nmda receptor`, `glutamate synapse`, `excitatory synapse`, `excitatory circuit`, `pyramidal cell`, `excitatory postsynaptic`
- **Inhibitory / GABAergic Interneuron**: `inhibitory neuron`, `gabaergic`, `interneuron`, `parvalbumin`, `somatostatin`, `inhibitory synapse`, `gaba neuron`, `inhibitory circuit`, `basket cell`, `gabaergic interneuron`
- **Dopaminergic / Monoaminergic Circuit**: `dopaminergic neuron`, `dopaminergic circuit`, `dopamine neuron`, `monoaminergic`, `serotonergic`, `noradrenergic`, `ventral tegmental area`, `substantia nigra neuron`, `dopamine release`, `catecholaminergic`
- **Glial Cell / Non-Neuronal Electrophysiology**: `astrocyte`, `microglia`, `oligodendrocyte`, `glial cell`, `non-neuronal activity`, `astrocyte electrophysiology`, `glial network`, `gliotransmission`, `tripartite synapse`, `neural-glial interaction`
- **Synaptic Transmission & Plasticity**: `synaptic transmission`, `synapse`, `synaptic plasticity`, `long-term potentiation`, `ltp`, `ltd`, `synaptic strength`, `synaptic current`, `miniature postsynaptic`, `mepsc`, `mipsc`
- **Inter-Organoid / Long-Range Network Connectivity**: `inter-region`, `inter-organoid`, `long-range connectivity`, `network connectivity`, `circuit connectivity`, `axonal projection`, `inter-region communication`, `connectional anatomy`, `long-range axon`, `cross-region`
- **Cell-Type-Specific Targeting & Genetic Identity**: `cell-type specific`, `cell-type-specific electrophysiology`, `genetically targeted`, `cell type identity`, `transcriptomic cell type`, `single-cell identity`, `cell class`, `cell-type targeting`, `molecularly defined`, `genetic cell type`
- **Sensory / Peripheral-Innervation Circuit**: `sensory innervation`, `sensory neuron`, `somatosensory`, `nociceptor`, `peripheral innervation`, `dorsal root ganglion`, `sensory circuit`, `mechanosensory`, `proprioceptive`, `sensory organoid`

The Neural Circuit/Cell-Type Focus dimension has the lowest classification rate of all five dimensions: only 41 of 122 projects were matched, leaving 81 unclassified and making this the most interpretively uncertain dimension. Within matched projects, Cortical Circuit/Neocortical Layer Dynamics leads at 9 projects (7.4% of sample) and $13.5M, followed by Cell-Type-Specific Targeting at 8 projects (6.6%) in this dimension, while Dopaminergic/Monoaminergic Circuit has 0 projects despite 44 broader NIH matches. Inhibitory/GABAergic Interneuron appears in only 1 project (0.8%) in this dimension against 55 broader NIH matches, and Glial Cell/Non-Neuronal Electrophysiology in 4 projects (3.3%) against 114 broader NIH matches - though the 114 broader NIH count for glial electrophysiology is anomalous relative to peer categories in this dimension and likely reflects broad keyword prevalence for glial biology rather than topic-specific activity, so it should be treated as directional only.

**Confidence: Low** - Evidence: only 41 of 122 projects classifiable in this dimension; 81 unclassified projects substantially limit interpretation; high unclassified rate may suppress apparent activity in multiple categories.

### Coverage Gap Signals

*Candidate gaps ranked by **share-normalized** comparison: broader-NIH share of the scope universe divided by sample share. A category only ranks as a gap when its broader-share materially exceeds its sample-share (>=2x). Raw count ratios are misleading when the sample universe (122 projects) and scope universe (2,299 projects) differ in size, so the shares are computed against those denominators directly. Signals here are still **directional** - the sample uses semantic matching, broader-NIH uses title-only keyword matching, and vocabulary drift can shift shares in either direction.*

**1. iPSC-Derived Neural Organoid** (Organoid / Model System Architecture)

- Analyzed sample: **0** projects (0.0% of 122 sample projects)
- Broader brain organoid electrophysiology: **248** matching projects (10.8% of 2,299 scope universe)
- **Share ratio:** broader-share is nullx sample-share - this is what identifies the gap, not the raw count difference.
- **Small-sample caveat:** the ratio here rests on zero topic project. A single classification change to the topic sample could shift the signal substantially. Treat as directional only.

iPSC-Derived Neural Organoid represents the most striking absence in the Organoid/Model System Architecture dimension: 0 of 122 projects (0.0% sample-share) despite 248 broader NIH matches, meaning the broader NIH portfolio's share for this category dwarfs the topic sample's share of zero. Given that iPSC derivation is the standard entry point for patient-specific disease modeling, the absence of this architecture within the organoid electrophysiology topic sample suggests an integration gap between the large iPSC-organoid field and electrophysiological characterization methods - a space where platforms combining iPSC differentiation protocols with electrophysiology readouts could find differentiated positioning. Note that the 248 broader NIH count is anomalously high relative to peer categories in this dimension and likely carries some keyword-inflation from general iPSC biology, so the directional signal - absent in topic, substantial elsewhere - is more reliable than any precise ratio.

**Confidence: Low** - Evidence: 0 sample projects vs 248 broader NIH matches; sample-share is 0.0% vs a substantial broader-NIH share; low confidence due to zero-count sample and probable keyword inflation in broader NIH count.

**2. Alzheimer's Disease / Age-Related Neurodegeneration** (Disease / Neurological Condition Modeled)

- Analyzed sample: **1** projects (0.8% of 122 sample projects)
- Broader brain organoid electrophysiology: **92** matching projects (4.0% of 2,299 scope universe)
- **Share ratio:** broader-share is 4.9x sample-share - this is what identifies the gap, not the raw count difference.
- **Small-sample caveat:** the ratio here rests on one topic project. A single classification change to the topic sample could shift the signal substantially. Treat as directional only.

Alzheimer's Disease/Age-Related Neurodegeneration appears in just 1 of 122 projects (0.8% sample-share) in the Disease/Neurological Condition Modeled dimension, while 92 broader NIH matches indicate this is one of the most heavily funded disease areas in the broader NIH portfolio - making the broader-share substantially higher than the topic sample's 0.8%. The single matched project carries $6.2M, hinting that when Alzheimer's does appear in this topic context it attracts significant funding, but the overall coverage within organoid electrophysiology remains minimal relative to the disease's prominence in wider NIH neuroscience funding. Platforms or research programs capable of validating Alzheimer's-relevant circuit phenotypes - such as network synchrony deficits or tau-associated electrophysiological signatures - using organoid models could occupy underserved territory at the intersection of two large funding streams.

**Confidence: Low** - Evidence: 1 sample project (0.8%) vs 92 broader NIH matches; low confidence due to near-zero sample count.

**3. Autism Spectrum Disorder / Syndromic ASD** (Disease / Neurological Condition Modeled)

- Analyzed sample: **1** projects (0.8% of 122 sample projects)
- Broader brain organoid electrophysiology: **63** matching projects (2.7% of 2,299 scope universe)
- **Share ratio:** broader-share is 3.3x sample-share - this is what identifies the gap, not the raw count difference.
- **Small-sample caveat:** the ratio here rests on one topic project. A single classification change to the topic sample could shift the signal substantially. Treat as directional only.

Autism Spectrum Disorder/Syndromic ASD appears in only 1 of 122 projects (0.8% sample-share) in the Disease/Neurological Condition Modeled dimension, compared to 63 broader NIH matches, meaning the broader-share is substantially higher than the topic sample's representation. ASD has strong biological rationale for organoid electrophysiology approaches given its synaptic and circuit-level underpinnings and the availability of patient-derived iPSC lines from well-characterized genetic subtypes (e.g., SHANK3, CHD8 variants). The convergence of a large broader NIH ASD portfolio with near-absent representation in organoid electrophysiology specifically suggests the topic-specific application of electrophysiological phenotyping to ASD organoid models remains underdeveloped relative to the disorder's overall research footprint.

**Confidence: Low** - Evidence: 1 sample project (0.8%) vs 63 broader NIH matches; low confidence due to near-zero sample count.

**4. Inhibitory / GABAergic Interneuron** (Neural Circuit / Cell-Type Focus)

- Analyzed sample: **1** projects (0.8% of 122 sample projects)
- Broader brain organoid electrophysiology: **55** matching projects (2.4% of 2,299 scope universe)
- **Share ratio:** broader-share is 2.9x sample-share - this is what identifies the gap, not the raw count difference.
- **Small-sample caveat:** the ratio here rests on one topic project. A single classification change to the topic sample could shift the signal substantially. Treat as directional only.

Inhibitory/GABAergic Interneuron appears in only 1 of 122 projects (0.8% sample-share) in the Neural Circuit/Cell-Type Focus dimension, against 55 broader NIH matches - a broader-share that is substantially higher than the topic sample's share. GABAergic interneuron dysfunction is implicated across multiple high-priority conditions including schizophrenia, epilepsy, and ASD, making electrophysiological characterization of inhibitory circuits in organoids a potentially high-value but currently underserved application. The very low classification rate of the Neural Circuit/Cell-Type Focus dimension overall (41 of 122 projects matched) means some additional GABAergic work may exist but be unclassified, so this signal should be treated as directional rather than definitive.

**Confidence: Low** - Evidence: 1 sample project (0.8%) vs 55 broader NIH matches; low confidence due to near-zero sample count and high unclassified rate in this dimension (81 of 122 unclassified).

### Strategic Implications

For a seed-stage or Series A investor evaluating the brain organoid electrophysiology space, the highest-signal positioning opportunities among underserved categories center on the convergence of iPSC-derived organoid architectures with electrophysiology readouts (0 of 122 projects in the analyzed sample, 0.0% sample-share, versus a substantial broader NIH footprint) and disease-specific applications in Alzheimer's (1 project, 0.8%) and ASD (1 project, 0.8%), where the broader NIH portfolio is orders of magnitude larger than topic-specific coverage. A platform company capable of combining patient-derived iPSC differentiation with scalable, validated electrophysiological phenotyping - and applying that platform to Alzheimer's or ASD circuit phenotypes - would address multiple ranked gaps simultaneously, with clinical validation milestones anchored to reproducible network-activity signatures that distinguish disease from healthy-baseline organoids. The Inhibitory/GABAergic Interneuron gap (1 project, 0.8% sample-share vs 55 broader NIH matches) further suggests that tools enabling cell-type-resolved inhibitory circuit characterization in organoids could complement disease-model applications and broaden platform utility across indication areas. Given that all four ranked opportunities rest on near-zero sample counts (0-1 projects each), conviction should be conditioned on observing independent replication of electrophysiological phenotypes in iPSC-organoid disease models before committing substantial capital.

**Confidence: Medium** - Evidence: top ranked opportunities at 0-1 sample projects each (0.0%-0.8% sample-share) vs broader NIH counts of 248, 92, 63, and 55 respectively; medium confidence because near-zero sample counts limit precision but directional signal across multiple dimensions is consistent.



---

## Investment Signals

### Technology Readiness Assessment

The majority of the 122 projects in this NIH sample sit at TRL 1-4, with basic research and early-stage biotools categories dominating the portfolio. Projects such as R43MH139259 (NeuroNexus long-term organoid electrophysiology system) and 1R43MH143569-01 (NeuroLux Organoid-CRADLE) represent SBIR Phase I efforts at TRL 3-4, while large platform grants at Allen Institute (5U01NS133760-03, Neuropixels Opto) and Johns Hopkins (5U01NS115587-04, Neuropixels NXT) suggest TRL 4-5 for recording hardware. Only 2 clinical trials appear in the linked data, and the organoid-specific arms of those trials are listed as N/A, indicating virtually no clinical-stage activity within this specific sample.

**Confidence: High** - Evidence: 122 projects reviewed; dominant category is basic research across the full project list; 2 clinical trials with N/A status; SBIR Phase I grants (R43 mechanism) represent the most commercially proximate organoid electrophysiology projects at fewer than 5 identified entries.

### Commercial Readiness

Commercialization pathways are present but early, concentrated primarily in recording hardware and platform tooling rather than therapeutic or diagnostic products. The most market-proximate entities are small companies - NeuroNexus (R43MH139259), NeuroLux (1R43MH143569-01), LeafLabs (R44AA033838, R43MH134730), SpikeGadgets (5R44MH136865-02, R44NS127692), CFD Research Corporation (R41TR006349 - HOPES platform), and Quiver Bioscience (R44MH122052) - all of which are in SBIR/STTR Phase I or II, suggesting products are 3-7 years from broad commercial deployment under optimistic assumptions. Missing elements for commercialization include regulatory-grade reproducibility standards for organoid-based assays, standardized electrophysiology benchmarks across organoid batches, and demonstrated clinical or drug-screening utility at scale.

**Confidence: Medium** - Evidence: 6-8 SBIR/STTR-mechanism projects identified in the full project list targeting organoid or large-scale electrophysiology commercialization; 0 projects in the sample explicitly describe FDA submission or CE marking pathways; no launched products identifiable from NIH project data alone.

### IP Concentration

Among the linked patents, the position is thin: only 5 total patents are associated with this research sample, with Stanford University holding 4 and Yale University holding 1, and 0 patents filed in the most recent 2-year window. With only 5 linked patents this sample is insufficient to characterize distribution, so no shape claim is drawn; the current wave of tooling innovation - particularly organoid-MEA integration, optogenetic-electrophysiology coupling, and long-term culture recording systems - is not reflected in granted NIH-linked patents in this sample. Freedom-to-operate conclusions cannot be drawn from this NIH-linked sample given only 5 linked patents, though undisclosed corporate IP (from entities such as Axion Biosystems, MaxWell Biosystems, or Multi Channel Systems, none of which appear in this NIH sample) is not captured here and likely represents a meaningful competitive consideration.

**Confidence: Medium** - Evidence: 5 total linked patents, 4 at Stanford, 1 at Yale, 0 filed in last 2 years; corporate assignee IP not represented in NIH-linked data; sample covers academic and SBIR-stage actors predominantly.

### Investment Risk Flags

**Key Risk:** The highest-priority risk for investors is the combination of organoid reproducibility limitations and the absence of any regulatory or industry-accepted functional benchmark, which together mean that even technically successful recording platforms may find adoption blocked by customers who cannot validate organoid assay outputs against accepted standards.

- **Scientific/Technical:** Organoid electrophysiology faces a fundamental reproducibility problem - batch-to-batch variability in organoid maturation and spontaneous network activity makes it difficult to establish the signal baselines required for drug screening or disease modeling, a challenge directly acknowledged in projects such as R00MH125329 (Arizona State, metabolic dysregulation) and F31NS132505 (Stanford, engineered hydrogel for reproducibility) but not yet solved at scale.
- **Regulatory:** There is no established regulatory framework for organoid-based electrophysiology assays as either a drug screening NAM (New Approach Methodology) or a diagnostic device, and the 2 clinical trials in the linked sample provide essentially no guidance on how FDA will treat organoid functional readouts as evidence, creating substantial pathway uncertainty for any investor-backed product targeting regulatory submission.
- **Competitive/Market:** Well-capitalized commercial MEA platform vendors operating outside the NIH-funded ecosystem - including Axion Biosystems, MaxWell Biosystems, and Multi Channel Systems - have existing customer bases and product lines in 2D and early 3D electrophysiology that could rapidly extend into the organoid segment, compressing the runway for SBIR-stage entrants identified in this sample.
- **Execution:** The most commercially proximate projects (NeuroNexus, NeuroLux, LeafLabs, CFD Research) are small companies in Phase I SBIR grants, meaning execution depends heavily on founding teams with limited capital, and none have yet demonstrated the manufacturing scale or go-to-market infrastructure needed to serve biopharma screening customers at throughput.

### Comparable Technologies

The closest commercial comparables are Axion Biosystems (Maestro MEA platform for 2D and nascent 3D neural cultures, raised approximately $40M, acquired by Agilent in 2021 for an undisclosed sum), and MaxWell Biosystems (high-density CMOS MEA, Series A-stage, Switzerland-based), both of which achieved early traction by serving academic neuroscience before expanding toward pharma screening - a trajectory the organoid electrophysiology entrants in this sample appear to be targeting. NIH funding stood at $39.3M in FY2024 and $52.5M in FY2025 (a 34% year-over-year increase); while two data points do not establish a trend, this shift is consistent with sustained NIH commitment to this tooling layer, which historically has preceded commercial platform consolidation by 5-8 years in analogous neurotechnology subsectors such as silicon probe development.

**Confidence: Medium** - Evidence: FY2024 and FY2025 figures drawn directly from the funding trend data provided; Axion/Agilent and MaxWell comparables are externally known but not represented in the NIH sample, so valuation benchmarks are not verifiable from this dataset alone; the 34% NIH funding increase is a single year-over-year data point without multi-year smoothing.
## Market Context

### Market Overview

*Market context below is synthesized from current web search results. See sources at the end of this section. NIH funding patterns are integrated to bridge public research and commercial activity.*

Brain organoid electrophysiology sits at the convergence of stem cell biology, neural engineering, and drug discovery, enabling researchers to record and stimulate functional neural activity within three-dimensional human tissue constructs in vitro. NIH funding patterns provide context: across 122 analyzed projects, approximately $129.8 million in public funding has been directed toward this space, with annual awards recorded at $39.3 million in FY2024 and $52.5 million in FY2025 (two data points do not establish a trend) (FY2026 shows $26.5 million YTD and remains incomplete). This trajectory of public investment appears to correlate with intensifying commercial activity, as roughly twenty identifiable companies now operate on the cerebral organoid segment alone as of 2025-2026. The concentration of NIH awards at institutions such as the Allen Institute, Stanford University, Johns Hopkins University, UC Berkeley, and the National Institute on Aging suggests that basic and translational research remains predominantly anchored in academic and government-affiliated centers rather than in industry labs - a pattern consistent with the field's relative early stage, where foundational technical problems around 3D electrode access and signal fidelity are still being resolved. Traditional planar microelectrode arrays (MEAs) and patch-clamp techniques have historically offered limited access to the full 3D architecture of organoid neural networks; next-generation platforms - including surface-embedded flexible electrodes, fully implantable mesh nanoelectronics, and high-density CMOS MEAs with tens of thousands of recording sites - are now being actively developed and commercialized to close this technical gap. The primary NIH research category skewing toward basic research may indicate that commercial translation is running somewhat ahead of the published mechanistic foundation, though NIH data alone cannot capture the full scope of private R&D investment flowing through industry channels.

Public-sector signals in 2025 have added further weight to the field's near-term relevance. In April 2025 the FDA announced it would promote organoid use in drug-safety testing as an alternative to animal models, and in September 2025 NIH committed $87 million to establish a new standardization center at Frederick National Laboratory. These institutional commitments suggest that regulatory and funding bodies view organoid platforms as practical tools for drug safety and efficacy testing, neurodevelopmental disease modeling covering conditions such as epilepsy, autism spectrum disorder, and Alzheimer's disease, and an emerging biocomputing application layer in which living neurons coupled to MEAs act as computational substrates. NIH funding patterns suggest that disease-modeling and basic neuroscience use cases are receiving the bulk of public investment at this stage; whether biocomputing and so-called organoid intelligence applications receive proportionate support within or outside this sample is not fully resolvable from the analyzed dataset alone, since private venture funding and international grants fall outside the NIH scope. Prominent brain organoid researchers have publicly cautioned against hype around organoid intelligence claims, warning that inflated assertions by biocomputing firms risk provoking regulatory and public backlash - a reputational and competitive risk the field is actively managing, and one that the strong academic-institutional weighting of NIH funding may help counterbalance by keeping primary research credibility grounded in peer-reviewed settings.

Taken together, the NIH funding data and commercial activity point to a field where public investment is building the scientific infrastructure - standardized methods, validated disease models, and novel electrode architectures - while commercial players race to productize platforms before those standards are fully settled. This timing dynamic represents both a risk and an opportunity for instrumentation companies and biocomputing startups alike: early movers can capture market share and shape emerging workflows, but products launched ahead of standardized benchmarks face adoption friction in regulated drug-testing contexts. The combination of rising NIH awards, the FDA's stated interest in organoid-based safety testing, and the NIH's new standardization center suggests that the next two to three years will be important for aligning commercial platforms with the credentialing frameworks that pharma and regulatory customers will require. NIH data represents publicly-funded academic research and does not capture private or industry R&D, so the full investment picture in this space is likely larger than the analyzed sample reflects.

**Market Sizing:** Direct sizing for brain organoid electrophysiology specifically is not separately tracked. The closest adjacent market is the broader organoids and spheroids market: $1.8 billion in 2025, projected to reach $9.6 billion by 2034 at a CAGR of 20.3% (Global Market Insights, 2025). A separate organoids-only estimate from Fortune Business Insights places the market at $1.43 billion in 2025, growing to $7.07 billion by 2034 at a CAGR of 19.41% (Fortune Business Insights, 2026).

### Key Players

*These players are identified from market reports and trade press, and may differ from the NIH-funded organizations analyzed elsewhere in this report.*

- Axion BioSystems (Maestro MEA platform for organoid electrophysiology)
- MaxWell Biosystems (HD-MEA MaxOne and MaxTwo systems)
- 3Brain AG (CorePlate high-density MEA for brain organoids)
- Multichannel Systems / Harvard Bioscience (MEA instruments)
- Cortical Labs (CL1 biological computer; MEA-based organoid computing)
- FinalSpark (Neuroplatform; remote-access organoid electrophysiology for biocomputing)
- AxoSim (CNS-3D brain organoid CRO services; acquired BrainSim IP from Vyant)
- a:head bio (cerebral organoid model focused on Dravet syndrome)
- BrainZell (high-throughput iPSC organoid production with electrophysiology readouts)
- Itay&Beyond (patient-derived organoids with MEA electrophysiology and AI analysis)
- Recursion Pharmaceuticals / Herophilus (AI-driven brain organoid phenotyping)
- HUB Organoids (acquired by Merck, December 2024)

### Recent Developments

- 2024-12: Merck announced acquisition of HUB Organoids, expanding its organoid technology portfolio and foundational patent position in organoid-based drug testing.
- 2025-04: The U.S. FDA announced it would promote the use of organoids in drug-safety testing as an alternative to animal models, a policy signal that could accelerate commercial adoption of functional (electrophysiology-enabled) organoid assays.
- 2025-04: Cortical Labs raised $10 million in a funding round led by Horizons Ventures, with Blackbird Ventures and In-Q-Tel participating, to scale its CL1 MEA-based biological computer.
- 2025-03: Cortical Labs commercially launched the CL1, billed as the world's first commercially available biological computer, integrating hundreds of thousands of human neurons onto a silicon chip with on-board MEA recording and stimulation.
- 2025-09: NIH committed $87 million to establish the Standardized Organoid Modeling (SOM) Center at Frederick National Laboratory for Cancer Research, targeting reproducible organoid protocols and regulatory adoption.
- 2025-10: NSF awarded $1.9 million to a UC Santa Cruz team to study the learning and reasoning potential of brain organoids, including electrophysiological mapping of organoid neural circuits.
- 2025-10: NSF launched its 'Biocomputing through EnGINeering Organoid Intelligence' (BEGIN OI) program, alongside DARPA investments in organoid-based biocomputing.
- 2025-11: Leading scientists and bioethicists publicly called for international oversight of human neural organoids, citing escalating complexity and electrophysiological sophistication; prominent researchers simultaneously warned that 'organoid intelligence' hype from biocomputing firms risks a field-wide backlash.
- 2025-10: Recursion Pharmaceuticals (via Herophilus partnership) and Recursion's Microglia Map project with Roche and Genentech completed a dataset of 46 million images of iPSC-derived microglia across ~100,000 CRISPR knockouts, a scale milestone for high-throughput brain organoid phenotyping.
- 2026-03: Cortical Labs demonstrated neurons learning to play the video game Doom using its MEA-based platform, extending its public proof-of-concept demonstrations beyond the 2022 Pong study.
- 2026-08: A peer-reviewed review in the International Journal of Stem Cells catalogued next-generation electrophysiological platforms for functional brain organoids, including surface-embedded, flexible, and fully implantable electrode designs capable of single-cell resolution over six-month longitudinal studies.

### Competitive Landscape

The competitive landscape for brain organoid electrophysiology spans at least three overlapping segments: (1) MEA instrument and consumables vendors, (2) organoid CRO and drug-discovery service providers, and (3) biocomputing platform companies. In the instruments tier, Axion BioSystems (Maestro MEA), MaxWell Biosystems (HD-MEA MaxOne/MaxTwo), and 3Brain (CorePlate) compete primarily on electrode density, throughput, and software analytics; Multichannel Systems (a Harvard Bioscience division) is an established incumbent across 2D and 3D formats. In the CRO and drug-discovery services tier, AxoSim - which counts 20 of the top 25 pharma companies among its customers - competes with Mimetas, Emulate, and CN Bio on physiological relevance and throughput. Specialist niche players such as a:head bio (Dravet syndrome focus) and Itay&Beyond (patient-derived organoids with AI-driven MEA readouts) are pursuing disease-specific or analytics-differentiated positions. At the biocomputing frontier, Cortical Labs (CL1, cloud access) and FinalSpark (Neuroplatform, remote MEA access) are the most visible commercial actors, though within the analyzed sample this segment remains thinly represented by rigorous, peer-reviewed demonstrations of computing performance, and prominent researchers have flagged that inflated capability claims could reshape regulatory and investor appetite for the entire field. Cross-cutting all segments, Merck's December 2024 acquisition of HUB Organoids and cumulative sector financings exceeding $2.1 billion globally through 2025 signal intensifying interest from large strategics and venture investors, competitive risks that could reshape the field as consolidation accelerates around proprietary organoid IP and MEA platform integrations.

### Sources

*Live web sources retrieved during report generation. Click to verify.*

- [www.gminsights.com/industry-analysis/organoids-and-spheroids-market](https://www.gminsights.com/industry-analysis/organoids-and-spheroids-market)
- [straitsresearch.com/report/organoids-market](https://straitsresearch.com/report/organoids-market)
- [www.fortunebusinessinsights.com/human-organoids-market-115158](https://www.fortunebusinessinsights.com/human-organoids-market-115158)
- [www.fortunebusinessinsights.com/organoids-market-104474](https://www.fortunebusinessinsights.com/organoids-market-104474)
- [www.polarismarketresearch.com/industry-analysis/human-organoids-market](https://www.polarismarketresearch.com/industry-analysis/human-organoids-market)
- [pubmed.ncbi.nlm.nih.gov/40739714/](https://pubmed.ncbi.nlm.nih.gov/40739714/)
- [www.futuremarketinsights.com/reports/organoids-market](https://www.futuremarketinsights.com/reports/organoids-market)
- [www.theinsightpartners.com/reports/organoids-market](https://www.theinsightpartners.com/reports/organoids-market)
- [www.strategicmarketresearch.com/market-report/human-organoids-market](https://www.strategicmarketresearch.com/market-report/human-organoids-market)
- [privatemarketsnews.substack.com/p/biological-computing-the-first-commercial](https://privatemarketsnews.substack.com/p/biological-computing-the-first-commercial)
- NIH RePORTER funding analysis



---

## IP Landscape

*Note: This analysis includes only patents linked to NIH-funded projects. Commercial patents and international filings may exist outside this sample. USPTO filing timelines also lag commercial activity by roughly 18-24 months, so very recent private R&D may not yet appear in patent data.*

**IP Landscape (this sample):** Insufficient sample to characterize (5 grant-linked patents - a landscape label like "concentrated" or "fragmented" requires at least 10 patents to be meaningful; the shape below is descriptive of this specific sample, not the broader IP landscape)

**Patent Holders in Sample:** STANFORD UNIVERSITY, YALE UNIVERSITY

**Recent Activity:** Within the NIH-linked sample, 0 of the 5 patents were filed in the last two years, suggesting no recent acceleration in NIH-project-linked patenting activity for this technical area - though this observation is limited to the linked sample and does not reflect broader commercial or international filing trends.

**Confidence: Low** - Evidence: 0 recent patents out of 5 total linked patents; commercial filers outside this NIH-linked sample may show a different activity pattern.

### Freedom to Operate Assessment

Among the NIH-linked patents in this sample, the 5 linked patents span 2 assignees across the following technical areas: functionally integrated forebrain spheroid assembly from human pluripotent stem cells (covered by multiple Stanford filings), oligodendrocyte culture and myelination modeling, and planar patch clamp electrode design (Yale). Any entrant working on brain organoid electrophysiology should review Stanford's forebrain spheroid claims carefully, as the repeated filings suggest active prosecution of that technical method - potential overlap with organoid assembly and integration workflows is a material FTO concern worth evaluating against specific product claims. The Yale planar patch clamp patent introduces a distinct electrode-design angle that may affect hardware-side approaches to organoid recording.

**Confidence: Low** - Evidence: 5 linked patents from 2 assignees; with a sample this small, the true commercial IP landscape - including filings by Axion Biosystems, MaxWell Biosystems, and other commercial MEA or patch-clamp instrument developers - is likely substantially larger and is not captured here.

The 5 linked patents in this sample are held by 2 academic institutions - Stanford University (4 patents) and Yale University (1 patent) - covering organoid assembly methods and patch clamp electrode technology. The 5 linked patents in this sample happen to be held by academic institutions; with a sample this small no distributional inference about where foundational IP is anchored can be drawn, though this is consistent with the early-stage nature of the field. Commercial patents from instrument and platform developers are not represented in this linked sample, so the full IP picture relevant to product development almost certainly extends well beyond what is visible here.

**Confidence: Low** - Evidence: 5 linked patents, 2 assignees, both academic; no commercial assignees appear in this NIH-linked subset.

### Strategic Implications

For an investor evaluating this space, the raw count of Stanford filings on forebrain spheroid assembly methods (4 of the 5 linked patents) is worth noting, but with only 5 linked patents this sample is insufficient to characterize the IP position; foundational organoid construction methods may still warrant licensing review if a portfolio company's platform relies on those specific assembly workflows. However, before drawing investment conclusions, the critical next step is running a full USPTO, Google Patents, and PATENTSCOPE search to surface commercial filings (particularly from MEA and electrophysiology instrument companies) that do not appear in this NIH-linked dataset. Academic IP at this stage is often licensable, which could represent an entry opportunity, but the absence of recent filings in the linked sample does not confirm that the broader patent environment is quiet - it may simply reflect the scope of what NIH project linkage captures.

**Confidence: Low** - Evidence: 5 linked patents from 2 academic assignees, 0 commercial assignees, 0 filings in the last 2 years; a sample this small cannot support portfolio-level investment conclusions without supplementary full-database patent search.

### Patent Analysis

Among the 5 linked patents in this sample, 4 are assigned to Stanford University and 1 to Yale University, covering two distinct technical areas: the Stanford patents address assembly and functional integration of human forebrain spheroids from pluripotent stem cells (including oligodendrocyte-containing variants for myelination studies), while the Yale patent covers planar patch clamp electrode design for high-throughput membrane current measurement. The Stanford forebrain spheroid patents appear in multiple filings covering the same core innovation - differentiation of pluripotent stem cells into subdomain structures that are then fused for analysis and screening - suggesting iterative prosecution of a foundational assembloid method. The Yale planar electrode patent addresses fabrication of polymer microelectrodes suited for multi-site patch clamp recording, including iPSC-derived cell types, which aligns with the infrastructure investment visible in the funded project sample. Notably, zero patents in this sample are dated within the past two years, which may indicate either a filing lag (patents typically publish 18 months after filing) or that much of the most recent tool innovation in this space has not yet reached granted patent status.

### Patent Summary

| Metric | Value |
|--------|-------|
| Total Patents (grant-linked) | 5 |
| Unique Assignees | 2 |
| Recent (2 years) | 0 |

### Key Patents

#### Assembly of Functionally-Integrated Forebrain Spheroids from Human Pluripotent Cells to Study Development and Disease
- **Patent #:** [10676715](https://www.granted.bio/patent/10676715)
- **Assignee:** STANFORD UNIVERSITY

> Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the lik...

#### ASSEMBLY OF FUNCTIONALLY INTEGRATED HUMAN FOREBRAIN SPHEROIDS AND METHODS OF USE THEREOF
- **Patent #:** [11279914](https://www.granted.bio/patent/11279914)
- **Assignee:** STANFORD UNIVERSITY

> Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the lik...

#### ASSEMBLY OF FUNCTIONALLY INTEGRATED HUMAN FOREBRAIN SPHEROIDS AND METHODS OF USE THEREOF
- **Patent #:** [12173313](https://www.granted.bio/patent/12173313)
- **Assignee:** STANFORD UNIVERSITY

> Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the lik...

#### PERSONALIZED 3D NEURAL CULTURE SYSTEM FOR GENERATING HUMAN OLIGODENDROCYTES AND STUDYING MYELINATION IN VITRO
- **Patent #:** [11760974](https://www.granted.bio/patent/11760974)
- **Assignee:** STANFORD UNIVERSITY

> Human pluripotent stem cells are differentiated in vitro into oligodendro-spheroids comprising oligodendrocytes for use in analysis, screening programs, and the like.

#### PLANAR PATCH CLAMP ELECTRODE
- **Patent #:** [6699697](https://www.granted.bio/patent/6699697)
- **Assignee:** YALE UNIVERSITY

> The present invention relates to ionic electrodes, particularly microelectrodes and electrode arrays, and also relates to fabrication methods for such electrodes. In particular, the present invention ...



---

## NIH Funding Analysis

Among the examined projects, our analysis reveals a strong concentration of NIH investment in tool development for human brain organoid electrophysiology, with biotools (51 projects) and basic research (47 projects) together accounting for the vast majority of the 122-project sample. The most heavily funded Precise-tier projects prioritize building next-generation recording infrastructure - including multi-electrode arrays, Neuropixels-class silicon probes, integrated optogenetic-electrophysiology systems, and long-term culture platforms - suggesting that the perceived bottleneck is measurement capability rather than biological hypotheses alone. Disease modeling applications appear prominently across the sample, with multiple projects targeting cortico-striatal circuits relevant to autism, schizophrenia, and epilepsy, and several others developing assembloid and organoid-on-chip systems for neurodevelopmental disorders. This sample recorded $39.3M in FY2024 and $52.5M in FY2025; two data points do not establish a trend, so no directional inference is drawn from these figures. FY2026 shows $26.5M as a partial-year YTD figure that should not be interpreted as a decline.

### Funding Summary

*Funding figures sum award amounts across all budget periods for each project. Each fiscal year reflects actual spend in that year, not the most recent budget period only. Totals only include projects that meet the topic-relevance threshold - umbrella support grants (e.g., P30 cancer centers) that host a relevant trial but cover many unrelated programs are intentionally excluded so the headline number stays topically attributable.*

| Metric | Value |
|--------|-------|
| Total Committed Funding | $129.8M |
| Active Projects | 122 |
| Funding Organizations | 70 |
| Principal Investigators | 131 |

### Funding by Year

<!-- chart:funding-by-year -->

| Year | Projects | Funding |
|------|----------|--------|
| FY2026 (YTD) | 44 | $26.5M |
| FY2025 | 72 | $52.5M |
| FY2024 | 66 | $39.3M |

*The Projects column counts each project in every year it received funding, so per-year counts sum to more than the 122-project sample total. Funding amounts are actual per-year spend from NIH RePORTER budget-period rows.*

*Through September 2026; FY2026 ends Sep 30, 2026. The YTD figure should not be compared directly to fully-reported prior years.*

### Top Funding Categories

<!-- chart:categories -->

| Category | Projects | Funding |
|----------|----------|--------|
| Basic Research | 47 | $54.7M |
| Biotools | 51 | $51.8M |
| Therapeutics | 13 | $10.9M |
| Medical Device | 5 | $9.1M |
| Infrastructure | 3 | $1.8M |
| Digital Health | 1 | $1.4M |
| Training | 2 | $144K |
## Key Research Projects

### Top Projects by Relevance

*Projects are ranked by semantic similarity to the topic - the most topic-relevant funded work first, not the largest awards. Funding is shown on each card as scale context (sum of award totals across all budget periods for each project). Latest activity is the most recent fiscal year the project received an award. Category is auto-assigned by AI classification and may occasionally misassign monitoring-oriented diagnostic projects as therapeutics - the abstract is the ground truth for what the project actually does.*

#### 1. Advanced culture and recording system for long-term electrophysiological profiling in human brain organoids
- **PI:** KIPKE, DARYL R, Neuronexus Technologies
- **Funding:** $899K (latest activity FY2026)
- **Category:** Biotools

**Insight:** This project directly targets the core limitation in brain organoid electrophysiology: the inability to sustain reliable neural recordings across the milliseconds-to-weeks timescales needed to track circuit maturation and disease-relevant functional changes. Developed by NeuroNexus Technologies, a commercial electrode manufacturer, the work combines novel culture hardware with recording system integration - a pairing that addresses both biological stability and signal acquisition in a single platform. Its commercial origin positions it as one of the few projects in this sample with a direct path from research prototype to catalog product, which is the type of revenue-adjacent signal the broader funding landscape currently lacks.

> Human “brain organoid” systems, cell culture models of human brain development derived from pluripotent stem cells, are important for disease studies and drug testing in human brain cells and circuits. This project will develop a novel electrophysiology system and critical components that, for the f...

[View Project ->](https://www.granted.bio/project/11291833)

#### 2. Development and Validation of a Compliant Reversible Actuator and Detector Leveraging Electrophysiology for Organoids (Organoid-CRADLE)
- **PI:** GOOD, CAMERON, Neurolux, Inc.
- **Funding:** $500K (latest activity FY2025)
- **Category:** Biotools

**Insight:** The Organoid-CRADLE project explicitly targets the measurement and manipulation of neural organoid function, proposing a tool designed to be more versatile, more informative, and less injurious than existing electrophysiology options - directly addressing signal quality and tissue damage tradeoffs that limit chronic recording in organoid models. The emphasis on reversible actuation alongside detection suggests a combined stimulation-recording architecture, which aligns with the dual read/write capability identified as a priority in optogenetic and MEA platform development across this sample. At $500K under a small business mechanism, it represents a lean, hardware-focused bet on conformable interface design rather than biological model development.

> Neural organoids are small clusters of human-origin brain cells that can help scientists develop new medicines and understand the brain. Unfortunately, measuring and manipulating their function is difficult. We plan to develop a new tool for this purpose that will be more versatile, more informative...

[View Project ->](https://www.granted.bio/project/11186733)

#### 3. Neuropixels Opto: Integrated Silicon Probes for Cell-Type-Specific Electrophysiology
- **PI:** SVOBODA, KAREL, Allen Institute
- **Funding:** $4.2M (latest activity FY2025)
- **Category:** Medical Device

**Insight:** Adjacent to brain organoid electrophysiology via shared instrumentation lineage - Neuropixels probes are widely used in high-density neural recording contexts - but this project is explicitly scoped to cell-type-specific recording and stimulation in living brains using silicon probe hardware; it does not address organoid models, organoid geometry, or in vitro culture electrophysiology. No direct methodological link to brain organoid electrophysiology; included for landscape context.

> Neurons in the human brain can be categorized into thousands of distinct “cell types,” each with unique properties, functions, and contributions to disease states. A comprehensive understanding of different cell types requires observing their electrical activity in living brains - however, the current...

[View Project ->](https://www.granted.bio/project/11145042)

#### 4. An electrophysiology platform that enables robust, scalable and long-term intracellular recording of cardiomyocytes
- **PI:** CUI, BIANXIAO, Stanford University
- **Funding:** $1.2M (latest activity FY2025)
- **Category:** Biotools

**Insight:** Adjacent to brain organoid electrophysiology via shared platform architecture - scalable, long-term intracellular recording of action potentials using an electrode-based system - but the biological target is cardiomyocytes and cardiac action potentials, not neural organoids or brain circuits. No direct methodological link to brain organoid electrophysiology; included for landscape context.

> Cardiac action potentials are crucial for their physiological functions in the human heart. This proposal aims to develop an electrophysiology platform that enables robust, scalable and long-term monitoring of cardiac action potentials. The instrument to be developed will bring new capabilities to e...

[View Project ->](https://www.granted.bio/project/11127465)

#### 5. Assembly and characterization of human cortico-striatal neural networks
- **PI:** SHCHEGLOVITOV, OLEKSANDR, Utah State Higher Education System--University of Utah
- **Funding:** $1.1M (latest activity FY2025)
- **Category:** Basic Research

**Insight:** This project sits at the center of the Basic Research funding category's dominant theme in this sample: generating human cortico-striatal assembloids from iPSCs and validating them as functional circuit models for ASD, schizophrenia, epilepsy, and mood disorders. Electrophysiology is the implied functional readout for characterizing cortico-striatal network development, consistent with the broader sample pattern of using neural activity as the primary validation metric for organoid disease models. The patient-specific iPSC framing also connects this work to the diagnostic and therapeutic translation potential flagged in the report's watchpoints, as patient-derived organoids are a prerequisite for individualized drug screening workflows.

> Much of human perception and behavior is governed by functioning brain networks. This project will develop a method for generating human cortico-striatal organoids from stem cells and demonstrate that these organoids can be used to model the development of human cortico-striatal networks. The abilit...

[View Project ->](https://www.granted.bio/project/11092839)

#### 6. Multi-modal, large-scale characterization of cellular and cell-type-specific effects with electric stimulation in rodent and human brain
- **PI:** LEE, SOO YEUN  (contact), Allen Institute
- **Funding:** $494K (latest activity FY2024)
- **Category:** Basic Research

**Insight:** Adjacent to brain organoid electrophysiology via shared electrophysiology methods - multipatch in vitro recording and high-density Neuropixels in vivo recording - applied to human single neurons and cell types in the context of electric stimulation; however, the project scope is rodent and human brain tissue, not organoid models. No direct methodological link to brain organoid electrophysiology; included for landscape context.

> Our goal is to gain a deeper mechanistic understanding of how external electric brain stimulation impacts the brain at the single-neuron and cell type-specific level. Using a number of techniques such in vitro multipatch electrophysiology and high-density Neuropixels in vivo recordings, this work wi...

[View Project ->](https://www.granted.bio/project/10893366)

#### 7. Multimodal Multi-Electrode Array (MEA) for Probing Tooth Root Organoid Maturation and Sensory Innervation
- **PI:** NARAYANAN, SHARADA, University of Pittsburgh at Pittsburgh
- **Funding:** $101K (latest activity FY2026)
- **Category:** Training

**Insight:** This project explicitly develops a multimodal MEA for use in an organoid model, integrating electrochemical sensing of neurotrophic factors with electrophysiological recording of sensory neuron activity - a dual-modality approach that extends beyond standard spike detection. The organoid target is a tooth root model rather than a brain organoid, so the neurological disease focus central to this sample's Basic Research category is absent, but the MEA hardware design challenge - stable, chronic, spatiotemporal recording in a three-dimensional organoid geometry - is directly shared with brain organoid electrophysiology platforms. As a training grant at $101K, its primary contribution to the field is workforce development in multimodal organoid instrumentation rather than platform commercialization.

> Organoid models, particularly those made from post-natal patient-derived tissue, represent an important step in the realization of personalized medicine. I am proposing to develop a multimodal microelectrode array (MEA) that can stably sense spatiotemporal patterning of neurotrophic factors and prob...

[View Project ->](https://www.granted.bio/project/11456628)

#### 8. Dissecting neocortical field potential dynamics using optical voltage imaging in genetically targeted cell-types
- **PI:** SCHNITZER, MARK J, Stanford University
- **Funding:** $1.1M (latest activity FY2026)
- **Category:** Biotools

**Insight:** Adjacent to brain organoid electrophysiology via shared interest in dissecting the cellular origins of population-level electrical signals - specifically, identifying how distinct genetically defined neuron classes contribute to field potentials such as LFP and ECoG - but the experimental system is cortical tissue with voltage imaging, not organoid electrophysiology. No direct methodological link to brain organoid electrophysiology; included for landscape context.

> Recordings of cortical field potentials are widely used in basic and clinical neuroscience and include electroencephalography (EEG), electrocorticography (ECoG) and local field potential (LFP) recordings, which all provide time-varying voltage signals reflecting neural population activity. However, ...

[View Project ->](https://www.granted.bio/project/11402559)

#### 9. Dissecting inter-region communication in human organoid models with dual-color optogenetic probes
- **PI:** XU, GUANGYU, University of Massachusetts Amherst
- **Funding:** $598K (latest activity FY2026)
- **Category:** Basic Research

**Insight:** This project directly addresses inter-region communication in organoid disease models using a purpose-built dual-color optogenetic system monolithically integrated with an MEA, enabling bidirectional circuit control and electrophysiological readout across multiple organoid regions and depths simultaneously. The explicit comparison to existing 3D organoid electrophysiology methods - and the claim that the proposed system achieves what RNA sequencing, standard organoid electrophysiology, and cell imaging cannot - positions it as a deliberate technical advance over the MEA platforms currently dominant in the Biotools funding category. The scalable pixel count and pitch design also suggests a path toward higher spatial resolution recordings, which is one of the hardware differentiation axes identified as separating prototype-stage tools from deployable products in this sample.

> This proposal aims to tailor design one high-precision optogenetic probing system, based on monolithic integration of close-packed dual-color LEDs and MEA, to dissect inter-region communication within regionalized organoid disease models. Specifically, we will investigate if our probes with scalable...

[View Project ->](https://www.granted.bio/project/11251646)

#### 10. Elucidating the molecular mechanisms behind human neurodevelopmental disorders using brain organoids
- **PI:** NOVITCH, BENNETT G, University of California Los Angeles
- **Funding:** $2.2M (latest activity FY2026)
- **Category:** Basic Research

**Insight:** This project uses brain organoids as the primary experimental platform to investigate mechanisms underlying neurodevelopmental disorders, with functional neural circuit activity - including oscillatory rhythms - serving as a key characterization readout that implies electrophysiological measurement. At $2.2M it is among the higher-funded Basic Research projects in this sample, and its dual focus on mechanism discovery and therapeutic strategy development connects the tool-building phase of organoid electrophysiology to the translational outcomes that the broader funding landscape has not yet delivered at scale. The prior demonstration of complex oscillatory network activity in the assembling team's organoid platform provides a validated functional baseline from which disease-specific perturbations can be systematically measured.

> Brain organoids are emerging as powerful tools for studying the mechanisms behind human brain development and disease. In our recent studies, we developed a platform for assembling functional neural circuits that exhibit surprisingly complex neural network activities such as oscillatory rhythms. In ...

[View Project ->](https://www.granted.bio/project/11243541)



---

## Clinical & Translational Activity

*Note: This analysis includes only clinical trials linked to NIH-funded projects. Industry-sponsored and international trials may exist outside this sample.*

The clinical trial sample linked to this query is small - 2 trials total, both Phase N/A - comprising 1 recruiting and 1 completed trial, with no terminated, withdrawn, or suspended trials in this particular sample. The recruiting trial targets Parkinson's disease using intracranial electrophysiology approaches to map neocortical microarchitecture of executive function, while the completed trial examined microelectrode applications in epilepsy, reflecting that the most direct clinical translations from electrophysiology tool development in this space address established neurological indications. The absence of later-phase trials in this sample is consistent with the NIH funding pattern, which is weighted heavily toward platform and tool development rather than interventional therapeutics, suggesting that brain organoid electrophysiology as a distinct modality remains predominantly preclinical. This limited clinical trial linkage may reflect the sample's focus on tool-building grants whose clinical value is expected to propagate through downstream drug discovery pipelines rather than direct trial sponsorship.

### Trial Summary

**By Phase**

| Phase | Count |
|-------|-------|
| N/A | 2 |

**By Status**

| Status | Count |
|--------|-------|
| Recruiting | 1 |
| Completed | 1 |

### Active Trials

#### Neocortical Microarchitecture of Executive Function
- **NCT ID:** [NCT06778135](https://www.granted.bio/trial/NCT06778135)
- **Phase:** Not specified
- **Status:** RECRUITING
- **Sponsor:** University of Colorado, Denver
- **Conditions:** Parkinson Disease
- **Enrollment:** 15 participants

#### Microelectrodes in Epilepsy
- **NCT ID:** [NCT05200455](https://www.granted.bio/trial/NCT05200455)
- **Phase:** Not specified
- **Status:** COMPLETED
- **Sponsor:** Dartmouth-Hitchcock Medical Center
- **Conditions:** Epilepsy
- **Enrollment:** 34 participants



---

## Key Organizations

*Top 15 of 70 funded organizations, ranked by NIH funding within the analyzed sample.*

| Organization | Projects | Funding | Pubs (grant-linked) | Trials (grant-linked) | Patents (grant-linked) |
|--------------|----------|---------|--------------------|-----------------------|------------------------|
| [Stanford University](https://www.granted.bio/org/STANFORD%20UNIVERSITY) | 8 | $9.5M | 53 | 0 | 4 |
| [Johns Hopkins University](https://www.granted.bio/org/JOHNS%20HOPKINS%20UNIVERSITY) | 8 | $8.6M | 8 | 0 | 0 |
| [Allen Institute](https://www.granted.bio/org/ALLEN%20INSTITUTE) | 5 | $17.8M | 24 | 0 | 0 |
| [University of Pittsburgh at Pittsburgh](https://www.granted.bio/org/UNIVERSITY%20OF%20PITTSBURGH%20AT%20PITTSBURGH) | 5 | $5.5M | 22 | 0 | 0 |
| [University of California Berkeley](https://www.granted.bio/org/UNIVERSITY%20OF%20CALIFORNIA%20BERKELEY) | 4 | $7.3M | 41 | 0 | 0 |
| [University of California Los Angeles](https://www.granted.bio/org/UNIVERSITY%20OF%20CALIFORNIA%20LOS%20ANGELES) | 4 | $3.5M | 6 | 0 | 0 |
| [University of California, San Diego](https://www.granted.bio/org/UNIVERSITY%20OF%20CALIFORNIA%2C%20SAN%20DIEGO) | 4 | $2.8M | 5 | 0 | 0 |
| [Harvard University](https://www.granted.bio/org/HARVARD%20UNIVERSITY) | 3 | $3.7M | 17 | 0 | 0 |
| [University of Southern California](https://www.granted.bio/org/UNIVERSITY%20OF%20SOUTHERN%20CALIFORNIA) | 3 | $3.6M | 9 | 0 | 0 |
| [University of Michigan at Ann Arbor](https://www.granted.bio/org/UNIVERSITY%20OF%20MICHIGAN%20AT%20ANN%20ARBOR) | 3 | $3.4M | 18 | 0 | 0 |
| [Icahn School of Medicine at Mount Sinai](https://www.granted.bio/org/ICAHN%20SCHOOL%20OF%20MEDICINE%20AT%20MOUNT%20SINAI) | 3 | $2.6M | 2 | 0 | 0 |
| [Yale University](https://www.granted.bio/org/YALE%20UNIVERSITY) | 3 | $2.0M | 5 | 0 | 1 |
| [Spikegadgets, LLC](https://www.granted.bio/org/SPIKEGADGETS%2C%20LLC) | 2 | $3.4M | 3 | 0 | 0 |
| [Indiana University Indianapolis](https://www.granted.bio/org/INDIANA%20UNIVERSITY%20INDIANAPOLIS) | 2 | $2.2M | 5 | 0 | 0 |
| [University of Colorado Denver](https://www.granted.bio/org/UNIVERSITY%20OF%20COLORADO%20DENVER) | 2 | $1.9M | 6 | 1 | 0 |

*Trials, patents, and publications counted here are those where an NIH grant belonging to this org was acknowledged. Patent assignee, trial sponsor, and publication first-author affiliation may differ from the org named on the underlying NIH grant. See the Patent Activity section for a separate view by assignee.*


---

## Key Researchers

*Investors often need names for diligence, partnership, and recruiting conversations. The PIs below are ranked by NIH funding within the analyzed sample.*

| Researcher | Projects | Funding | Organization |
|------------|----------|---------|-------------|
| [MARSAN, ELISE  (contact)](https://www.granted.bio/researcher/MARSAN%2C%20ELISE%20%20(contact)) | 1 | $6.2M | National Institute on Aging |
| [ARKHIPOV, ANTON](https://www.granted.bio/researcher/ARKHIPOV%2C%20ANTON) | 1 | $5.0M | Allen Institute |
| [PASCA, SERGIU](https://www.granted.bio/researcher/PASCA%2C%20SERGIU) | 2 | $4.9M | Stanford University |
| [ADESNIK, HILLEL](https://www.granted.bio/researcher/ADESNIK%2C%20HILLEL) | 2 | $4.3M | University of California Berkeley |
| [SVOBODA, KAREL](https://www.granted.bio/researcher/SVOBODA%2C%20KAREL) | 1 | $4.2M | Allen Institute |
| [REID, R CLAY](https://www.granted.bio/researcher/REID%2C%20R%20CLAY) | 1 | $4.2M | Allen Institute |
| [SORENSEN, STACI A](https://www.granted.bio/researcher/SORENSEN%2C%20STACI%20A) | 1 | $4.0M | Allen Institute |
| [KRISHNAN, YAMUNA](https://www.granted.bio/researcher/KRISHNAN%2C%20YAMUNA) | 1 | $3.4M | University of Chicago |
| [HARRIS, TIMOTHY D](https://www.granted.bio/researcher/HARRIS%2C%20TIMOTHY%20D) | 2 | $3.3M | Johns Hopkins University |
| [MILLER, EVAN WALKER](https://www.granted.bio/researcher/MILLER%2C%20EVAN%20WALKER) | 2 | $2.9M | University of California Berkeley |
| [KARLSSON, MATTIAS PETER](https://www.granted.bio/researcher/KARLSSON%2C%20MATTIAS%20PETER) | 1 | $2.8M | Spikegadgets, LLC |
| [MENG, ELLIS](https://www.granted.bio/researcher/MENG%2C%20ELLIS) | 1 | $2.5M | University of Southern California |
| [HASHINO, ERI](https://www.granted.bio/researcher/HASHINO%2C%20ERI) | 2 | $2.2M | Indiana University Indianapolis |
| [NOVITCH, BENNETT G](https://www.granted.bio/researcher/NOVITCH%2C%20BENNETT%20G) | 1 | $2.2M | University of California Los Angeles |
| [STUDER, LORENZ P.](https://www.granted.bio/researcher/STUDER%2C%20LORENZ%20P.) | 1 | $2.1M | Sloan-Kettering Inst Can Research |


---

## Key Publications

*Note: This analysis includes only publications linked to NIH-funded projects and may not represent the complete body of literature in this field. PubMed indexing typically lags publication date by 1-3 months for peer-reviewed articles; preprints appear faster but are not peer-reviewed.*

The 486 publications linked to this sample address a wide range of scientific questions spanning ion channel biophysics, circuit-level electrophysiology, voltage imaging methodology, and organoid disease modeling, with bioRxiv (96 papers) being the most represented outlet - suggesting the field is publishing rapidly through preprint channels, consistent with a technically fast-moving area. Methodological advances observed in the sample include kilohertz-frame-rate two-photon voltage imaging capable of monitoring over 200 neurons simultaneously in vivo (FACED 2.0), 1,024-channel hybrid voltage/current-clamp neural interface chips, and dual-color voltage indicator and optogenetic approaches for dissecting cell-type-specific circuit dynamics. Several publications address the mechanistic basis of electrical stimulation effects - including intracortical microstimulation depression dynamics and motor cortical TMS-induced analgesia via endogenous opioid plasticity - reflecting the dual role of electrophysiology as both a readout and an intervention tool. The appearance of work in Nature Methods, Nature Neuroscience, Neuron, and PNAS alongside the heavy preprint volume suggests the field spans both established high-impact venues and a rapid-dissemination culture, indicating a research community that is actively building methodological consensus while simultaneously pushing applied frontiers.

### Must-Read Publications

#### 1. Delivery of cytokines via encapsulated human astrocytes for neural immunomodulation.
- **Journal:** Biomaterials | **Year:** 2026
- **PMID:** [40882323](https://pubmed.ncbi.nlm.nih.gov/40882323)

**Why it matters:** This paper establishes a coculture platform combining encapsulated human iPSC-derived astrocytes with neuron-astrocyte-microglia organoids, directly enabling in vitro testing of neuroinflammatory modulators in organoid systems. For investors, it represents a convergence of cell therapy and organoid technology with a clear path toward implantable neuromodulatory devices.

**Key finding:** Alginate-encapsulated human astrocytes engineered to express IL-1Ra reduced organoid reactivity to inflammatory cytokines and were successfully implanted into rodent brain while secreting the therapeutic protein.

#### 2. Behavioral strategy shapes activation of the Vip-Sst disinhibitory circuit in visual cortex.
- **Journal:** Neuron | **Year:** 2024
- **PMID:** [38447579](https://pubmed.ncbi.nlm.nih.gov/38447579)

**Why it matters:** Adjacent to brain organoid electrophysiology via shared interest in cortical circuit-level neural activity and inhibitory interneuron dynamics; not a brain organoid electrophysiology project itself. For investors, the demonstration that behavioral strategy differentially recruits defined interneuron circuits provides circuit-level targets relevant to therapeutic intervention.

**Key finding:** Individual mice use mixtures of visual comparison and statistical timing strategies, and the Vip-Sst disinhibitory circuit in visual cortex is selectively activated during the visual comparison strategy.

### Publication Summary

- Total linked publications: 486
- Unique journals: 162

**Top Journals:**

- bioRxiv : the Preprint Server for Biology (96)
- Nature Communications (22)
- Cell Reports (17)
- Neuron (14)
- Nature (14)



---

## Next Steps

*Concrete actions the report suggests based on what's above. Not exhaustive - use these as a starting checklist you can extend.*

- **Verify the iPSC-derived organoid white-space signal before pricing it in.** The Coverage Gap Signals section flags iPSC-Derived Neural Organoid as absent from this 122-project sample despite 248 broader-NIH projects. Before treating this as a clean commercial opening, investigate whether the gap reflects a real funding blind spot in organoid electrophysiology specifically, or whether adjacent NIH portfolios (stem cell biology, neurodevelopment, systems neuroscience) already fund this work under different taxonomy labels. If the gap holds after cross-checking RePORTER with alternative MeSH terms, it may signal an early-stage commercial window worth tracking.

- **Run a full IP landscape search independent of this report's patent count.** The linked-patent sample contains only 5 patents - too small to assess freedom-to-operate risk or assignee distribution. Run a full USPTO, Google Patents, and PATENTSCOPE search using terms covering brain organoid electrophysiology, multi-electrode array (MEA) recording, and organoid-on-chip approaches. The NIH-linked count is structurally blind to commercial filings and international applications, so any diligence conclusion drawn from the 5-patent figure alone would be unreliable.

- **Assess the Alzheimer's and ASD disease-modeling signals as staged diligence hypotheses.** The Coverage Gap Signals section shows Alzheimer's Disease / Age-Related Neurodegeneration (sample=1, broader NIH=92) and Autism Spectrum Disorder / Syndromic ASD (sample=1, broader NIH=63) as underrepresented in this sample. Before mapping these to a commercial thesis, verify whether the underrepresentation is a taxonomy artifact - check whether disease-modeling organoid work in these indications is funded under neurodegenerative disease or psychiatric genetics programs rather than electrophysiology-specific mechanisms. If the gap is real, both indications carry large and well-capitalized patient-advocacy and pharma interest, making them worth tracking as potential IND-enabling application areas.

- **Map the inhibitory interneuron / GABAergic circuit gap to specific assay and platform capabilities.** The Inhibitory / GABAergic Interneuron category shows sample=1 against broader-NIH=55 (see Coverage Gap Signals section). For an investor, this is a technical readiness question as much as a funding question: assess whether current organoid electrophysiology platforms can reliably resolve GABAergic circuit-level signals at throughput relevant to drug screening, and whether any preclinical-stage companies in your pipeline have this capability benchmarked. This technical milestone - reproducible inhibitory interneuron electrophysiology in organoids - is worth tracking as a value juncture for platform companies in this space.

- **Use the $129.8M NIH funding baseline to calibrate market formation stage.** The total NIH investment across 122 projects and 70 funded organizations indicates a field that is active but distributed, not yet organized around a dominant platform or clinical application. For a venture or corporate development context, this distribution pattern - reviewed in the Key Organizations table - suggests the market is likely pre-consolidation. Benchmark any company claims about market leadership or platform dominance against this distribution; a field with 70 funded organizations and only 2 trials in the NIH-linked sample is still primarily a research tools and preclinical-services market.

- **Treat the near-absence of clinical trials as a stage indicator, not a negative signal.** Only 2 trials appear in the post-filter sample. This reflects the developmental stage of the field rather than a regulatory or efficacy problem - organoid electrophysiology is predominantly a platform and assay technology. For diligence purposes, the near-term commercial value is likely in research instrumentation, contract research services, and drug-screening applications rather than therapeutic products. Set milestone triggers around first IND-enabling studies using organoid electrophysiology readouts as a primary endpoint, which would mark a meaningful stage transition.

- **Review the funded abstract and publication record in the top-project cluster before forming a technology thesis.** The top 5 PIs by project count collectively hold 7 projects (see Key Researchers table). Rather than profiling individuals, read the funded abstracts and peer-reviewed publications associated with projects in that cluster (searchable via NIH RePORTER by project number) to understand which methodological approaches - MEA, calcium imaging, patch clamp, or hybrid modalities - are attracting repeat funding. This will help you assess which platform architectures have demonstrated enough reproducibility to attract sustained NIH confidence, which is a meaningful proxy for technical maturity when evaluating early-stage companies.

- **Monitor the SBIR/STTR mechanism activity in this portfolio as a commercial pipeline signal.** Review the grant mechanism breakdown in the report's funding analysis section to identify what share of the $129.8M flows through SBIR and STTR awards. Companies holding active SBIR Phase II awards in organoid electrophysiology are often 12-36 months from seeking Series A or strategic partnership capital. Running a RePORTER filter on SBIR/STTR awards in this topic area - combined with your IP landscape search - will give you a forward-looking view of which commercial entities are being validated by NIH peer review right now, independent of what is visible in startup databases.
## About This Report

### Methodology

This report analyzes a curated subset of NIH-funded research projects most relevant to **brain organoid electrophysiology**. Projects were identified using semantic search (AI-based conceptual matching) and filtered by match quality.

**Search Interpretation Used:** Standard - "brain organoid electrophysiology including neural organoids and patch clamp recording"

**Note on Funding Figures:** Per-project funding amounts shown in this report are the sum of award totals across all budget periods for each project (not just the most recent year). Funding-by-year figures show actual spend per fiscal year drawn from the underlying NIH RePORTER budget-period rows, so a multi-year project contributes to each year it received funding. The current NIH fiscal year (Oct 1 - Sep 30) is partial when this report is generated; that year is labeled "(YTD)" in tables and charts and should not be compared directly to fully-reported prior years.

**Note on Funding Attribution:** Clinical trials are surfaced through two paths - direct linkage to topically-relevant projects, *and* semantic similarity between the trial's own title and the topic (using the same vector-embedding mechanism that powers project search, gated by a dedicated trial-inclusion threshold). The second path catches trials that sit under broad institutional umbrella awards (e.g., P30 cancer center support grants, CTSA hubs) whose underlying parent grant covers many unrelated programs. Those trials are reported because their titles are clearly about the topic, but their umbrella grants' funding is *not* rolled into Total Committed Funding - only projects whose own abstracts clear the project-relevance threshold contribute to funding totals. This keeps the headline funding number topically attributable rather than inflated by institutional overhead grants that happen to host one relevant program among many.

**Match Quality Tiers:**

| Tier | Similarity | Description |
|------|------------|-------------|
| **Precise** | ≥50% | Highly relevant - directly addresses the topic |
| **Balanced** | ≥35% | Relevant - related research with clear connection |

**Sample Composition:**

| Metric | Value |
|--------|-------|
| Projects Analyzed | 122 |
| Precise Matches | 122 |
| Balanced Matches | 0 |
| Total Committed Funding | $129.8M |
| Organizations | 70 |
| Principal Investigators | 131 |

**Sample Interpretation:**

- **All 122 matches are Precise** (similarity ≥50%). This is not a tuned threshold - it reflects the topic mapping to a tightly-bounded research area where most relevant NIH grants land above the 50% similarity cutoff. Broader topics with less coherent literature produce mixed Precise + Balanced splits (typically 60/40 to 80/20). Note that "Precise" measures semantic similarity to the query, not perfect topical fit - a project can score above the threshold and still touch adjacent research areas (e.g., a project whose main focus is diagnostic biomarkers but whose abstract mentions sepsis biomarkers as comparator work). Treat this signal as "the field's vocabulary aligns well with our query," not as "every project is a pure topic match."



**Linked Data:**

| Data Type | Count | Source |
|-----------|-------|--------|
| Clinical Trials | 2 | ClinicalTrials.gov |
| Patents | 5 | USPTO |
| Publications | 486 | PubMed |

### Limitations

This analysis focuses on **depth over breadth**, capturing publicly-funded academic research. It does not include privately-funded industry R&D or international research outside NIH grants.

*Data current as of September 22, 2026.*

---

*Analysis generated by granted.bio. Browse more analyses or generate your own: https://www.granted.bio*
